<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Phenobarbital: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Phenobarbital: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Phenobarbital: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11826" href="/d/html/11826.html" rel="external">see "Phenobarbital: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12698" href="/d/html/12698.html" rel="external">see "Phenobarbital: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F57654257"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risks from concomitant use with opioids (Sezaby):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of phenobarbital products and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. If a decision is made for concomitant use of these drugs, limit dosages and durations to the minimum required, and follow patients for signs and symptoms of respiratory depression and sedation.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dependence and withdrawal reactions after use for a longer duration than recommended (Sezaby):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The continued use of phenobarbital may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although indicated only for short-term use, if used for a longer duration than recommended, abrupt discontinuation or rapid dosage reduction may precipitate acute withdrawal reactions, which can be life-threatening. For patients receiving for longer duration than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue use.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Abuse, misuse, and addiction with unapproved use in adolescents and adults (Sezaby):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Not approved for use in adolescents or adults. The unapproved use, in adolescents and adults exposes them to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of phenobarbital commonly involve concomitant use of other drugs, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55474154"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Sezaby</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F209005"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiseizure Agent, Barbiturate;</li>
<li>
                        Barbiturate</li></ul></div>
<div class="block doa drugH1Div" id="F208963"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2421fee4-a1cb-4381-8225-702f5276ef91">Alcohol withdrawal syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alcohol </b>
<b>withdrawal syndrome (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Severe or refractory withdrawal (adjunctive agent): Note: </b>For use in severe or refractory withdrawal (eg, delirium tremens) despite benzodiazepine therapy. <b>Safety:</b> Use only by clinicians experienced with phenobarbital therapy in settings (eg, critical care or emergency department) with monitoring for adverse effects (eg, oversedation, respiratory compromise) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511109','lexi-content-ref-Hoffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511109','lexi-content-ref-Hoffman.1'])">Ref</a></span>). Consider dose reduction in patients at risk for oversedation or respiratory compromise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30876654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30876654'])">Ref</a></span>). Optimal dosing and regimens have not been identified; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Example regimens are presented below:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initial: 130 mg <b>or</b> 260 mg once, followed by 130 mg every 15 to 30 minutes as needed until resolution of symptoms. Once symptoms are controlled, use maintenance dose of 130 to 260 mg/day in 2 to 3 divided doses for 3 to 5 days, followed by a taper of 10% dose reduction/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511109','lexi-content-ref-20825805','lexi-content-ref-Hoffman.1','lexi-content-ref-29925291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511109','lexi-content-ref-20825805','lexi-content-ref-Hoffman.1','lexi-content-ref-29925291'])">Ref</a></span>). Maximum dose has not been established; some experts do not exceed cumulative doses of 15 mg/kg within the first 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hoffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hoffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM (use only if IV access is not available):</b> 60 to 260 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511109'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a5b0cb2b-97d8-4c58-b27d-3b3dfbcb0a46">Sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV, IM:</b> 30 to 120 mg/day in 2 to 3 divided doses; maximum: 400 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Preoperative sedation: <b>IM:</b> 100 to 200 mg 60 to 90 minutes before surgery.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98f720da-4e7e-4163-a85a-e8df3fee1f21">Status epilepticus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus:</b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>American Epilepsy Society recommendations:</i> 15 mg/kg as a single dose. <b>Note:</b> AES recommends phenobarbital as a second line option only if first line options (lorazepam, diazepam, or midazolam) or other second line options (eg, fosphenytoin, valproic acid, levetiracetam) are unavailable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neurocritical Care Society recommendation:</i> 20 mg/kg (infused at 50 to 100 mg/minute); if necessary, may repeat once after 10 minutes with an additional 5 to 10 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Additional respiratory support may be required particularly when maximizing loading dose or if concurrent sedative therapy. Repeat doses administered sooner than 10 to 15 minutes may not allow adequate time for peak CNS concentrations to be achieved and may lead to CNS depression.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3bdc9ea7-289f-4752-8056-e3eef3f779c9">Seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures:</b> Maintenance dose:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> Usual dosage range (limited data available): 2 mg/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Murphy.1','lexi-content-ref-Winter.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Murphy.1','lexi-content-ref-Winter.1'])">Ref</a></span>). <b>Note: </b>Dosage should be individualized based upon clinical response and serum concentration; 2 mg/kg/day typically produces a steady-state level of 20 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Winter.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Winter.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer's labeling:</i>
<b>Oral:</b> Dosing in the prescribing information may not reflect current clinical practice. 60 to 200 mg/day <b>or </b>50 to 100 mg 2 to 3 times daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ecd13be3-c659-4f23-8b00-1a6046b8643c">Sedative/hypnotic withdrawal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedative/hypnotic withdrawal (off-label use):</b> Several regimens have been evaluated:</p>
<p style="text-indent:-2em;margin-left:4em;">Taper following dosage conversion: <b>Oral:</b> Initial daily requirement is determined by substituting phenobarbital in an equivalent dose to the baseline medication (clonazepam 1 mg = phenobarbital 60 mg was used in the study). Divided the calculated baseline total dose into 4 doses and administer every 6 hours for 2 days; then decrease the daily requirement by 10% per day over the next 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8348204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8348204'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Fixed dose taper: <b>Oral:</b> Initial 200 mg, followed by 100 mg every 4 hours for 5 doses, 60 mg every 4 hours for 4 doses, and then 60 mg every 8 hours for 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22285834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22285834'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> When discontinuing chronic therapy, gradually taper dose over ≥6 months (eg, may reduce dose in decrements of 10% to 25% of original dose on a monthly basis) to minimize risk of withdrawal syndrome, including increased seizure frequency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18760938','lexi-content-ref-Sirven.1','lexi-content-ref-17586097']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18760938','lexi-content-ref-Sirven.1','lexi-content-ref-17586097'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991024"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; reduced doses are recommended. The following guidelines have been recommended by some clinicians:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥10 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: Administer dose every 12 to 16 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-16970741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-16970741'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis (moderately dialyzable [20% to 50%]): Administer dose before dialysis and 50% of dose after dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: 35% to 40% removed; administer 50% of normal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-24365310','lexi-content-ref-16970741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-24365310','lexi-content-ref-16970741'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous renal replacement therapy (CRRT): Administer normal dose and monitor levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988239"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer’s labeling; reduced doses are recommended. Phenobarbital exposure is increased with hepatic impairment; use with caution</p></div>
<div class="block doe drugH1Div" id="F208964"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F208981"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12698" href="/d/html/12698.html" rel="external">see "Phenobarbital: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c5aa0b6-3984-4ca1-b571-a8eb67460863">Seizures, maintenance therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, maintenance therapy: Note:</b> Maintenance dose usually starts 12 hours after loading dose: Dosage should be individualized based upon clinical response and serum concentration; once-daily doses usually administered at bedtime in children and adolescents.</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling: Infants, Children, and Adolescents: Oral: 3 to 6 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">Alternate dosing: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16473127','lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16473127','lexi-content-ref-Kliegman.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children ≤5 years: 3 to 5 mg/kg/day in 1 to 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:8em;">Children &gt;5 years and Adolescents: 2 to 3 mg/kg/day in 1 to 2 divided doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98f720da-4e7e-4163-a85a-e8df3fee1f21">Status epilepticus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus:</b> Infants, Children, and Adolescents: IV: Initial: 15 to 20 mg/kg; maximum dose: 1,000 mg/dose; may repeat with an additional 5 to 10 mg/kg 10 minutes after loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-22528274','lexi-content-ref-30075875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-22528274','lexi-content-ref-30075875'])">Ref</a></span>). <b>Note:</b> Additional respiratory support may be required particularly when maximizing loading dose or if concurrent sedative therapy; repeat doses administered sooner than 10 to 15 minutes may not allow adequate time for peak CNS concentrations to be achieved and may lead to CNS depression.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="af6f56c3-5b00-41d9-9916-3fd5d5dd5458">Hyperbilirubinemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperbilirubinemia:</b> Limited data available: Infants and Children: Oral: Usual range: 3 to 8 mg/kg/day in 2 to 3 divided doses; doses up to 10 mg/kg/day in divided doses have been used in case reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17519457','lexi-content-ref-Nelson.1996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17519457','lexi-content-ref-Nelson.1996'])">Ref</a></span>); for the treatment of hyperbilirubinemia in Crigler-Najjar Syndrome, a dose of 5 mg/kg/day has been used to reduce serum bilirubin concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>); not recommended for management of biliary cirrhosis due to sedation and other adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30070375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30070375'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Conversion of PENTobarbital to PHENobarbital (withdrawal prevention)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tobias.1','lexi-content-ref-10890677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tobias.1','lexi-content-ref-10890677'])">Ref</a></span>): <b>Note:</b> For use when total cumulative PENTobarbital dose is ≥25 mg/kg or duration ≥5 to 7 days; this conversion method is based on preliminary data in mechanically-ventilated patients. Closely monitor respiratory status and evaluate patient for withdrawal symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Limited data available: <b>Note:</b> Dosing is based on last PENTobarbital dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Discontinue PENTobarbital infusion; administer half of the PHENobarbital IV loading dose 6 hours after discontinuation of PENTobarbital infusion; 6 hours later, administer the second half of the PHENobarbital IV loading dose; administer each loading dose over 1 hour.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Loading dose:</i> Based on last pentobarbital dose as follows: IV:</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">PENTobarbital Infusion Rate</p>
<p style="text-indent:0em;">(mg/kg/hour)</p></th>
<th align="center">
<p style="text-indent:0em;">PHENobarbital IV Total Loading Dose</p>
<p style="text-indent:0em;">(mg/kg)</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">1 to 2</p></td>
<td align="center">
<p style="text-indent:0em;">8</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center">
<p style="text-indent:0em;">15</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">3 to 4</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose:</i> IV: Begin 6 hours after total loading dose completed: Maintenance dose is <sup>1</sup>/<sub>3</sub> of initial loading dose every 12 hours. Once patient is stabilized, may switch to oral therapy and begin tapering 10% to 20% weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tobias.1','lexi-content-ref-10890677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tobias.1','lexi-content-ref-10890677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51153446"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">No specific dosage adjustment provided in manufacturer's labeling; reduced doses are recommended. The following guidelines have been used by some clinicians (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: <b>Note:</b> Renally adjusted dose recommendations are based on doses of 3-7 mg/kg/day every 12-24 hours</p>
<p style="text-indent:-2em;margin-left:6em;">GFR ≥10 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Decrease normal dose by 50% and administer every 24 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent hemodialysis [moderately dialyzable (20% to 50%)]: Supplemental dose may be needed during and after dialysis depending on individual seizure threshold</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis (PD): 40% to 50% removed; amount varies depending on number of cycles</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy (CRRT): Monitor serum concentrations; a case report suggests that clearance and volume of distribution increased with CVVH; more frequent and higher dosing may be necessary in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pasko.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pasko.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51153447"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in manufacturer's labeling. Phenobarbital exposure is increased with hepatic impairment; reduced doses are recommended; use with caution.</p></div>
<div class="block arsc drugH1Div" id="F56962223"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Barbiturates, including phenobarbital, may cause cardiovascular (CV) adverse reactions such as <b>hypotension</b> and <b>bradycardia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31191808','lexi-content-ref-24886712','lexi-content-ref-20826962']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31191808','lexi-content-ref-24886712','lexi-content-ref-20826962'])">Ref</a></span>) in all ages. Evidence is limited to rare studies that suggest a negative effect of IV barbiturates on cardiac function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1562334','lexi-content-ref-31191808','lexi-content-ref-24886712','lexi-content-ref-20826962']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1562334','lexi-content-ref-31191808','lexi-content-ref-24886712','lexi-content-ref-20826962'])">Ref</a></span>). Hypotension requiring fluid resuscitation and vasopressor use was reported in 32% of adult patients receiving continuous IV pentobarbital (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24886712']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24886712'])">Ref</a></span>). Another study in adults receiving IV thiopental reported a 30% to 40% decrease in cardiac index (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20826962']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20826962'])">Ref</a></span>). A direct depressant effect on contractility of the left ventricle with a transient decrease in systolic blood pressure was reported in up to 30% of children receiving IV phenobarbital; a return to baseline was observed within 12 to 24 hours of the loading dose and prior to initiation of the maintenance dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31191808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31191808'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; left ventricular dysfunction with decreased ejection fraction due to direct depression of myocardial function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31191808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31191808'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; occurred 30 minutes after an IV loading dose in one study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31191808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31191808'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• IV formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31191808','lexi-content-ref-24886712','lexi-content-ref-20826962']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31191808','lexi-content-ref-24886712','lexi-content-ref-20826962'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid IV administration</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting left ventricular dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20826962']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20826962'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Coronary artery disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20826962']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20826962'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent benzodiazepines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35219012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35219012'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Phenobarbital may cause CNS adverse reactions, including <b>drowsiness</b>, <b>ataxia</b>, <b>vertigo</b>, <b>cognitive dysfunction, changes in thinking</b>, and <b>memory impairment</b>, in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23673774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23673774'])">Ref</a></span>). Phenobarbital, like other antiseizure medications, may lead to a cerebellar syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6424397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6424397'])">Ref</a></span>). Patients with dementia may experience cognitive adverse reactions on relatively low doses more frequently than patients without dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23673774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23673774'])">Ref</a></span>). Incidence of CNS adverse reactions is unclear; one study described subjective cognitive impairment as “common” in patients with epilepsy on antiseizure medications that may lead to dosage change or discontinuation in &gt;10% of patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19010446','lexi-content-ref-23673774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19010446','lexi-content-ref-23673774'])">Ref</a></span>). Some data suggest more cognitive adverse reactions with phenobarbital compared to other antiseizure medications (eg, phenytoin, carbamazepine, levetiracetam, valproate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15329080','lexi-content-ref-24051577','lexi-content-ref-2314578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15329080','lexi-content-ref-24051577','lexi-content-ref-2314578'])">Ref</a></span>). In pediatric patients, phenobarbital has been shown to decrease cognitive performance, increase <b>behavioral changes</b> (including ADHD), and has long-term negative effects on learning ability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2220307','lexi-content-ref-2242106','lexi-content-ref-23673774','lexi-content-ref-662511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2220307','lexi-content-ref-2242106','lexi-content-ref-23673774','lexi-content-ref-662511'])">Ref</a></span>); adverse neurodevelopmental outcomes have also been reported in neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24051577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24051577'])">Ref</a></span>). Drowsiness is mostly transient, persisting for days to weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6424397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6424397'])">Ref</a></span>). Patients may also experience <b>paradoxical central nervous system stimulation</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29071470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29071470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23673774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23673774'])">Ref</a></span>); depresses the sensory cortex, motor activity, and cerebellar function.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Drowsiness often occurs with phenobarbital initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6424397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6424397'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses/higher serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6424397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6424397'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Comorbid dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23673774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23673774'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Phenobarbital is associated with a variety of delayed hypersensitivity reactions, ranging from mild with <b>maculopapular rash</b> to severe cutaneous adverse reactions (SCARs) including<b> Stevens-Johnson syndrome</b>/<b>toxic epidermal necrolysis</b> (SJS/TEN) and <b>drug reaction with eosinophilia and systemic symptoms</b> (DRESS) (often referred to as a hypersensitivity syndrome) in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12897635','lexi-content-ref-11346057','lexi-content-ref-14505048','lexi-content-ref-29501520','lexi-content-ref-30689189','lexi-content-ref-31997613','lexi-content-ref-20064188','lexi-content-ref-15824335','lexi-content-ref-32245300','lexi-content-ref-26221907']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12897635','lexi-content-ref-11346057','lexi-content-ref-14505048','lexi-content-ref-29501520','lexi-content-ref-30689189','lexi-content-ref-31997613','lexi-content-ref-20064188','lexi-content-ref-15824335','lexi-content-ref-32245300','lexi-content-ref-26221907'])">Ref</a></span>). In cases of DRESS, long-term complications may arise after drug discontinuation including type 1 diabetes mellitus and alopecia areata universalis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19811415','lexi-content-ref-18475056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19811415','lexi-content-ref-18475056'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic. Delayed hypersensitivity reactions, including maculopapular eruptions and SCARs, are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31708349','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31708349','lexi-content-ref-26339470'])">Ref</a></span>). Accumulation of toxic arene oxide metabolite due to a defect in epoxide hydrolase-mediated detoxification may lead to cell necrosis or apoptosis or may initiate secondary immunological responses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22794330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22794330'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed hypersensitivity reactions: Varied; maculopapular rash usually occurs 3 to 20 days following initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25933949','lexi-content-ref-1831121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25933949','lexi-content-ref-1831121'])">Ref</a></span>). SCARs usually occur 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-NICE.1'])">Ref</a></span>); re-exposure may lead to more rapid onset (usually with 1 to 4 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-1831121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-1831121'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic factors: Presence of HLA-A*01:01 with phenobarbital hypersensitivity and HLA-B*13:01 with SCARs in Thai children may be potential risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27554620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27554620'])">Ref</a></span>). HLA-B*1502 may increase risk of SJS in Han Chinese (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24496695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24496695'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of DRESS to an aromatic anticonvulsant (eg, phenytoin, carbamazepine, phenobarbital): An increased risk has been suggested, although one study showed that phenobarbital may be tolerated in some family members who develop reactions to phenytoin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17896897','lexi-content-ref-1750433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17896897','lexi-content-ref-1750433'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Reactivation of viruses: Viral reactivation, in particular human herpesvirus 6 (HHV-6) reactivation may be associated with a prolonged and more severe course of DRESS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12112085','lexi-content-ref-17854362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12112085','lexi-content-ref-17854362'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity: High degree of cross-reactivity exists between aromatic antiseizure medications, including phenytoin, carbamazepine, phenobarbital, primidone, and oxcarbazepine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15304627','lexi-content-ref-22794330','lexi-content-ref-3198757','lexi-content-ref-20888266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15304627','lexi-content-ref-22794330','lexi-content-ref-3198757','lexi-content-ref-20888266'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Age: Pediatric patients &lt;12 years and older adult patients may be at risk for severe SCARs associated with aromatic antiseizure medications, including phenobarbital (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30955419','lexi-content-ref-29501520','lexi-content-ref-22794330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30955419','lexi-content-ref-29501520','lexi-content-ref-22794330'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Radiation therapy (especially cranial irradiation): May increase the risk of cutaneous reactions, including erythema multiforme and SJS/TEN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10071329','lexi-content-ref-7947221','lexi-content-ref-23340399','lexi-content-ref-17589805']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10071329','lexi-content-ref-7947221','lexi-content-ref-23340399','lexi-content-ref-17589805'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Respiratory depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Phenobarbital may cause <b>respiratory depression</b>, a known adverse reaction of phenobarbital in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30159873','lexi-content-ref-22326977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30159873','lexi-content-ref-22326977'])">Ref</a></span>). Incidence is unclear; one study in pediatric patients with status epilepticus found 1 out of 30 patients developed respiratory depression that required bag and mask ventilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22326977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22326977'])">Ref</a></span>). In another retrospective review of eight adult patients who received phenobarbital for status epilepticus (5 to 19.8 mg/kg), none required intubation but one needed supplemental oxygen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30159873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30159873'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; at high concentrations, phenobarbital has been found to directly activate GABA-A receptors even in the absence of GABA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23683707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23683707'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; immediately after administration of high dose IV formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30159873','lexi-content-ref-22326977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30159873','lexi-content-ref-22326977'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<b>
<i></i></b></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid IV administration</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting obstructive lung disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of benzodiazepines and opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22326977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22326977'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of antiseizure medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal ideation/tendencies</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antiseizure medications have been associated with suicidal ideation and suicidal tendencies in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19496806','lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19496806','lexi-content-ref-22994856'])">Ref</a></span>). However, the FDA meta-analysis has been criticized due to several important limitations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19496806','lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19496806','lexi-content-ref-22994856'])">Ref</a></span>). The risk of suicide is increased in epilepsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19453718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19453718'])">Ref</a></span>), but the occurrence of suicidal ideation/tendencies in epilepsy is multi-factorial. While some antiseizure medications (but not all) have been associated with treatment-emergent psychiatric effects such as anxiety and depression, other factors such as post-ictal suicidal behavior and pertinent patient history must also be evaluated to provide an accurate assessment of risk for any individual drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22994856'])">Ref</a></span>). A cohort of 28 children with epilepsy showed that treatment with phenobarbital compared with carbamazepine or no antiseizure medication, was associated with higher rates of <b>depression </b>(38% vs 0%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2339032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2339032'])">Ref</a></span>). Patients with a history of depression treated with phenobarbital whose medication was changed to carbamazepine or no medication showed nonsignificant trends toward declines in both the frequency and severity of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2339032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2339032'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; peak incidence of suicidality across antiseizure medications (not specific to individual agents) has been noted to occur between 1 and 12 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28190254','lexi-content-ref-20388896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28190254','lexi-content-ref-20388896'])">Ref</a></span>). A review of clinical trials noted that risk extended from 1 week to 24 weeks of therapy, corresponding to the duration of most trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>History of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818889'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F208917"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (neonates: 16%)<span class="lexi-table-link-container"> (<a aria-label="Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypotension')">table 1</a>)</span><span class="table-link" style="display:none;">Hypotension</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypotension" frame="border" id="lexi-content-hypotension" rules="all">
<caption style="text-align:center;">
<b>Phenobarbital: Adverse Reaction: Hypotension</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Phenobarbital)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Levetiracetam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Phenobarbital)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neonates</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Seizures</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Change in appetite (feeding disorder; neonates: 16%)<span class="lexi-table-link-container"> (<a aria-label="Change in Appetite table link" class="lexi-table-link" data-table-id="lexi-content-change-in-appetite" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-change-in-appetite')">table 2</a>)</span><span class="table-link" style="display:none;">Change in Appetite</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Change in Appetite" frame="border" id="lexi-content-change-in-appetite" rules="all">
<caption style="text-align:center;">
<b>Phenobarbital: Adverse Reaction: Change in Appetite</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Phenobarbital)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Levetiracetam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Phenobarbital)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neonates</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Seizures</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Feeding disorder</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Sedated state (neonates: 16%)<span class="lexi-table-link-container"> (<a aria-label="Sedated State table link" class="lexi-table-link" data-table-id="lexi-content-sedated-state" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-sedated-state')">table 3</a>)</span><span class="table-link" style="display:none;">Sedated State</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Sedated State" frame="border" id="lexi-content-sedated-state" rules="all">
<caption style="text-align:center;">
<b>Phenobarbital: Adverse Reaction: Sedated State</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Phenobarbital)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Levetiracetam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Phenobarbital)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neonates</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Seizures</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Changes in respiration (neonates: 25% [including respiratory depression and respiratory insufficiency])<span class="lexi-table-link-container"> (<a aria-label="Changes in Respiration table link" class="lexi-table-link" data-table-id="lexi-content-changes-in-respiration" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-changes-in-respiration')">table 4</a>)</span><span class="table-link" style="display:none;">Changes in Respiration</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Changes in Respiration" frame="border" id="lexi-content-changes-in-respiration" rules="all">
<caption style="text-align:center;">
<b>Phenobarbital: Adverse Reaction: Changes in Respiration</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Phenobarbital)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Levetiracetam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Phenobarbital)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neonates</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Seizures</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Including respiratory depression and respiratory insufficiency</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (neonates: 3%)<span class="lexi-table-link-container"> (<a aria-label="Bradycardia table link" class="lexi-table-link" data-table-id="lexi-content-bradycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bradycardia')">table 5</a>)</span><span class="table-link" style="display:none;">Bradycardia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bradycardia" frame="border" id="lexi-content-bradycardia" rules="all">
<caption style="text-align:center;">
<b>Phenobarbital: Adverse Reaction: Bradycardia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Phenobarbital)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Levetiracetam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Phenobarbital)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neonates</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Seizures</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia (neonates: 3%)<span class="lexi-table-link-container"> (<a aria-label="Hyponatremia table link" class="lexi-table-link" data-table-id="lexi-content-hyponatremia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyponatremia')">table 6</a>)</span><span class="table-link" style="display:none;">Hyponatremia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyponatremia" frame="border" id="lexi-content-hyponatremia" rules="all">
<caption style="text-align:center;">
<b>Phenobarbital: Adverse Reaction: Hyponatremia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Phenobarbital)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Levetiracetam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Phenobarbital)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neonates</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Seizures</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Circulatory shock, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (areata universalis; associated with hypersensitivity syndrome) (Huang 2009), eczema, exfoliative dermatitis, fixed drug eruption (Chadly 2014), maculopapular rash (Nafei 2019), Stevens-Johnson syndrome (Mockenhaupt 2005), toxic epidermal necrolysis (Mockenhaupt 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Type 1 diabetes mellitus (associated with hypersensitivity syndrome) (Zou 2008), vitamin D deficiency (Hahn 1972)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukemoid reaction (associated with hypersensitivity syndrome) (Zeng 2013), megaloblastic anemia, thrombocytopenia (associated with hypersensitivity syndrome) (Nafei 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, drug reaction with eosinophilia and systemic symptoms (Baruzzi 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, anxiety, ataxia (Iivanainen 1983), behavioral changes (Gaitatzis 2003, Wolf 1978), central nervous system depression (Iivanainen 1983), changes in thinking (Iivanainen 1983), cognitive dysfunction (Calendre 1990, Farwell 1990, Gaitatzis 2003), confusion, decreased deep tendon reflex (absent), depression (Brent 1990), dizziness, drowsiness (Iivanainen 1983), hallucination, hangover effect, headache, hypotonia, impaired consciousness, insomnia, lethargy, memory impairment (Iivanainen 1983), nervousness, neurological abnormality, nightmares, paradoxical central nervous system stimulation (Verrotti 2018), psychiatric disturbance, vertigo, withdrawal syndrome (with longer duration of use than recommended)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hyperkinetic muscle activity, laryngospasm, osteomalacia, rheumatism (Jha 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, hypoventilation</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F208935"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to phenobarbital, barbiturates, or any component of the formulation; marked hepatic impairment; dyspnea or airway obstruction; porphyria (manifest and latent).</p>
<p style="text-indent:-2em;margin-left:2em;">Additional contraindications: Solution for injection: Intra-arterial or SUBQ administration; use in patients with a history of sedative/hypnotic substance use disorder; nephritic patients (large doses).</p></div>
<div class="block war drugH1Div" id="F208914"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anemia: Use with caution in patients with severe anemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Avoid use in patients showing the premonitory signs of hepatic coma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoadrenalism: Use with caution in patients with hypoadrenalism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Sezaby: May precipitate life-threatening, acute attacks of porphyria in patients with acute porphyria; symptoms may include abdominal pain, anxiety, confusion, hyponatremia, limb pain, muscle weakness, and seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Substance use disorder: Use with caution in patients with a history of substance use disorder; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in patients who are debilitated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fever: Use with caution in patients with a fever.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May cause paradoxical responses, including agitation and hyperactivity. Phenobarbital has been associated with cognitive deficits in children receiving therapy for complicated febrile seizures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Avoid perivascular extravasation or intra-arterial injection due to highly alkaline nature. Discontinue use with signs of discoloration, pain, swelling, or temperature change in the limb. Too rapid administration may cause severe respiratory depression, apnea, laryngospasm, hypertension or vasodilation with fall in blood pressure. Phenobarbital IV may require ≥15 minutes before reaching peak concentrations in the brain; injecting phenobarbital until the convulsions stop may lead to severe barbiturate induced depression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute pain: Use with caution in patients with acute or chronic pain; paradoxical excitement could be induced or important symptoms could be masked.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Antiseizure medications should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878590"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Phenobarbital elixir and oral solutions contain 15% alcohol.</p></div>
<div class="block foc drugH1Div" id="F208927"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Elixir, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/5 mL (5 mL, 7.5 mL, 15 mL, 473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 65 mg/mL (1 mL); 130 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sezaby: 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F208910"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323673"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Elixir</b> (PHENobarbital Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/5 mL (per mL): $0.19 - $0.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (PHENobarbital Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">65 mg/mL (per mL): $21.00 - $31.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">130 mg/mL (per mL): $43.20 - $82.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Sezaby Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $160.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (PHENobarbital Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $0.10 - $0.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16.2 mg (per each): $0.12 - $0.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.11 - $0.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">32.4 mg (per each): $0.17 - $0.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $0.20 - $0.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">64.8 mg (per each): $0.19 - $0.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">97.2 mg (per each): $0.25 - $1.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.26 - $0.74</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867919"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Elixir, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/5 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg/mL (1 mL); 120 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg, 30 mg, 60 mg, 100 mg</p></div>
<div class="block csi drugH1Div" id="F209007"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-IV</p></div>
<div class="block adm drugH1Div" id="F208932"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">May be administered IV, IM, or orally.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, rapid IV administration &gt;60 mg/minute should be avoided. In the setting of status epilepticus, the Neurocritical Care Society recommends administration at a rate of 50 to 100 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>). May be an irritant; avoid extravasation. Intra-arterial injection is contraindicated. Discontinue administration of injection if patient complains of limb pain. Avoid subcutaneous administration.</p>
<p style="text-indent:-2em;margin-left:2em;">For IM administration, inject deep into muscle. Do not exceed 5 mL per injection site due to potential for tissue irritation.</p></div>
<div class="block admp drugH1Div" id="F52613576"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer liquid formulations with an accurate measuring device; do not use a household teaspoon.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Do not administer intra-arterially. SUBQ administration is not recommended. Avoid extravasation. Avoid small veins, such as those on the dorsum of the hand or wrist, and avoid varicose veins. Preference is given to larger veins. Inject slow IV; the maximum rate recommended by the manufacturer for adults is 60 mg/minute. In the setting of status epilepticus, the Neurocritical Care Society recommends administration at a rate of 50 to 100 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>). Administration over 15 to 30 minutes has been recommended in neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>); large loading doses (eg, 40 mg/kg) in neonates have been infused over 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9506654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9506654'])">Ref</a></span>). Too rapid administration may result in severe respiratory depression, apnea, laryngospasm, hypertension, or vasodilation with fall in blood pressure. Discontinue administration of injection if there is any evidence of pain, swelling, discoloration, or temperature change in the limb.</p></div>
<div class="block use drugH1Div" id="F208931"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation:</b> Use as a sedative</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures:</b> Management of generalized tonic-clonic, status epilepticus, and partial seizures; management of neonatal seizures in term and preterm infants (Sezaby only).</p></div>
<div class="block off-label drugH1Div" id="F25744667"><span class="drugH1">Use: Off-Label: Adult</span><p>Alcohol withdrawal syndrome; Sedative/hypnotic withdrawal</p></div>
<div class="block mst drugH1Div" id="F209015"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">PHENobarbital may be confused with PENTobarbital, Phenergan, phenytoin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Phenobarbital is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its high rate of physical dependence, tolerance to sleep benefits, and increased risk of overdose at low dosages (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F209000"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP2C9 (minor), CYP2E1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP1A2 (weak), CYP2A6 (weak), CYP2B6 (weak), CYP2C9 (weak), CYP3A4 (strong), UGT1A1</p></div>
<div class="block dri drugH1Div" id="F208919"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abiraterone Acetate.  Management: Avoid when possible. If the combination cannot be avoided, increase abiraterone acetate dosing frequency from once daily to twice daily during combined use. Reduce abiraterone dose back to the prior dose and frequency once strong inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Acalabrutinib.  Management: Avoid co-administration of strong CYP3A inducers in patients taking acalabrutinib. If strong CYP3A inducers cannot be avoided, increase the dose of acalabrutinib to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: PHENobarbital may increase the metabolism of Acetaminophen. Specifically, formation of the hepatotoxic NAPQI metabolite may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adagrasib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Adagrasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: PHENobarbital may decrease the serum concentration of Afatinib.  Management: Consider increasing the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of phenobarbital with afatinib. Reduce afatinib dose back to the original afatinib dose 2 to 3 days after discontinuation of phenobarbital.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Albendazole: PHENobarbital may decrease serum concentrations of the active metabolite(s) of Albendazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfacalcidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Alfacalcidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inducers (Strong) may decrease the serum concentration of ALfentanil.  Management: If concomitant use of alfentanil and strong CYP3A4 inducers is necessary, consider dosage increase of alfentanil until stable drug effects are achieved. Monitor patients for signs of opioid withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Alpelisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Amiodarone. CYP3A4 Inducers (Strong) may decrease the serum concentration of Amiodarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inducers (Strong) may decrease the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: CYP3A4 Inducers (Strong) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.  Management: Avoid concurrent use of apixaban with strong CYP3A4 inducers whenever possible. Use of a strong CYP3A4 inducer with apixaban should be strictly avoided in any patient who is using an agent (either the CYP3A4 inducer or a third drug) that induces P-gp.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apremilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of ARIPiprazole.  Management: For indications other than major depressive disorder: double the oral aripiprazole dose over 1 to 2 weeks and closely monitor. Avoid use of strong CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Patients taking the 441 mg dose of aripiprazole lauroxil increase their dose to 662 mg if used with a strong CYP3A4 inducer for more than 14 days. No dose adjustment is necessary for patients using the higher doses of aripiprazole lauroxil.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether and Lumefantrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May decrease the serum concentration of PHENobarbital. PHENobarbital may decrease the serum concentration of Atazanavir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avacopan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avapritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Barnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bazedoxifene: PHENobarbital may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or, if bazedoxifene is combined with estrogen therapy, an increased risk of endometrial hyperplasia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Belumosudil.  Management: Increase the dose of belumosudil to 200 mg twice daily when coadministered with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: PHENobarbital may enhance the CNS depressant effect of Benzhydrocodone. PHENobarbital may decrease serum concentrations of the active metabolite(s) of Benzhydrocodone. Specifically, phenobarbital may decrease serum concentrations of hydrocodone.  Management: Avoid use of benzhydrocodone and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased benzhydrocodone efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Betamethasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: PHENobarbital may decrease the serum concentration of Bictegravir.  Management: When possible consider using an alternative antiseizure drug with concurrent bictegravir, emtricitabine, and tenofovir alafenamide. If the combination must be used, monitor closely for evidence of reduced antiviral effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisoprolol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bisoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brexpiprazole.  Management: If brexpiprazole is used together with a strong CYP3A4 inducer, the brexpiprazole dose should gradually be doubled over the course of 1 to 2 weeks. Decrease brexpiprazole to original dose over 1 to 2 weeks if the strong CYP3A4 inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivaracetam: PHENobarbital may decrease the serum concentration of Brivaracetam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bromocriptine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brotizolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brotizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: PHENobarbital may enhance the CNS depressant effect of Buprenorphine. PHENobarbital may decrease the serum concentration of Buprenorphine.  Management: Avoid use of buprenorphine and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased buprenorphine efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: CYP2B6 Inducers (Weak) may decrease the serum concentration of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inducers (Strong) may decrease the serum concentration of BusPIRone.  Management: Consider alternatives to this combination. If coadministration of these agents is deemed necessary, monitor patients for reduced buspirone effects and increase buspirone doses as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabazitaxel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabazitaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: UGT1A1 Inducers may decrease the serum concentration of Cabotegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.  Management: Avoid use of strong CYP3A4 inducers with cabozantinib if possible. If combined, increase cabozantinib capsules (Cometriq) by 40 mg from previous dose, max 180 mg daily. Increase cabozantinib tablets (Cabometyx) by 20 mg from previous dose, max 80 mg daily<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcifediol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Calcifediol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Canagliflozin: PHENobarbital may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabidiol: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Cannabidiol. CYP3A4 Inducers (Strong) may decrease the serum concentration of Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Capivasertib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capmatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Capmatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inducers (Strong) may decrease the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cariprazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carmustine: PHENobarbital may decrease the serum concentration of Carmustine.  Management: Consider alternatives to phenobarbital when using carmustine. If combined, monitor for reduced carmustine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cenobamate: May increase the serum concentration of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ceritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Charcoal, Activated: May decrease the serum concentration of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): PHENobarbital may decrease the serum concentration of Chloramphenicol (Systemic). Chloramphenicol (Systemic) may increase the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproPAMIDE: CYP3A4 Inducers (Strong) may decrease the serum concentration of ChlorproPAMIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholestyramine Resin: May decrease the serum concentration of PHENobarbital. Management: Administer phenobarbital at least 1 hour before or 4 to 6 hours after administration of cholestyramine in order to minimize the risk for any significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilnidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cilnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: CYP3A4 Inducers (Strong) may decrease the serum concentration of Citalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.  Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A4 inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and may impair clarithromycin efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClonazePAM: CYP3A4 Inducers (Strong) may decrease the serum concentration of ClonazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Strong) may decrease the serum concentration of CloZAPine.  Management: Avoid use with strong CYP3A4 inducers when possible. If combined, monitor patients closely and consider clozapine dose increases. Clozapine dose reduction and further monitoring may be required when strong CYP3A4 inducers are discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: PHENobarbital may decrease the serum concentration of Cobicistat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: PHENobarbital may enhance the CNS depressant effect of Codeine. PHENobarbital may decrease the serum concentration of Codeine.  Management: Avoid use of codeine and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased codeine efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Colchicine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Copanlisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: May enhance the hepatotoxic effect of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Monitor closely for reduced cyclosporine concentrations when combined with strong CYP3A4 inducers. Cyclosporine dose increases will likely be required to maintain adequate serum concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproterone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cyproterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: PHENobarbital may decrease the serum concentration of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Daclatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): May enhance the adverse/toxic effect of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Dapsone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: May decrease the serum concentration of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid concurrent use of dasatinib with strong CYP3A4 inducers when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: UGT1A1 Inducers may decrease the serum concentration of Deferasirox.  Management: Avoid concomitant use of deferasirox and UGT1A1 inducers when possible. If combined, consider a 50% increase in the initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical response to guide further dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: CYP3A4 Inducers (Strong) may decrease the serum concentration of Delamanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: PHENobarbital may decrease the serum concentration of Delavirdine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of DexAMETHasone (Systemic).  Management: Consider dexamethasone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced dexamethasone efficacy. Consider avoiding this combination when treating life threatening conditions (ie, multiple myeloma).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May increase the serum concentration of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inducers (Strong) may decrease the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inducers (Strong) may decrease the serum concentration of DilTIAZem.  Management: Consider alternatives to this combination when possible. If combined, monitor for decreased diltiazem efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May enhance the adverse/toxic effect of Products Containing Ethanol. Management: Do not use disulfiram with dosage forms that contain ethanol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOCEtaxel: CYP3A4 Inducers (Strong) may decrease the serum concentration of DOCEtaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: PHENobarbital may decrease the serum concentration of Dolutegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Domperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doravirine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Doravirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxercalciferol: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Doxercalciferol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Duvelisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Duvelisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dydrogesterone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dydrogesterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebastine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ebastine. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ebastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: CYP3A4 Inducers (Strong) may decrease the serum concentration of Efavirenz. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elagolix. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix, Estradiol, and Norethindrone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elagolix, Estradiol, and Norethindrone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elbasvir and Grazoprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: PHENobarbital may decrease the serum concentration of Elvitegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Encorafenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enfortumab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enfortumab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Entrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enzalutamide: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Enzalutamide. CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.  Management: Consider using an alternative agent that has no or minimal CYP3A4 induction potential when possible. If this combination cannot be avoided, increase the dose of enzalutamide from 160 mg daily to 240 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eplerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eravacycline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eravacycline.  Management: Increase the eravacycline dose to 1.5 mg/kg every 12 hours when combined with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Erdafitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Erlotinib.  Management: Avoid the combination of erlotinib and strong CYP3A4 inducers whenever possible. If this combination must be used, increase erlotinib dose by 50 mg increments every 2 weeks as tolerated, to a maximum of 450 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: CYP3A4 Inducers (Strong) may decrease the serum concentration of Escitalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eslicarbazepine: PHENobarbital may decrease the serum concentration of Eslicarbazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Estazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: CYP3A4 Inducers (Strong) may decrease the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eszopiclone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eszopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethosuximide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ethosuximide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etizolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide. If combined, monitor patients closely for diminished etoposide response and need for etoposide dose increases.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide Phosphate.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide phosphate. If these combinations cannot be avoided, monitor patients closely for diminished etoposide phosphate response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoricoxib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoricoxib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etravirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Concomitant use of everolimus and strong CYP3A4 inducers is generally not recommended. However, if combined, monitor for decreased everolimus concentrations and effects, and adjust everolimus dose as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Evogliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Evogliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Increase the exemestane dose to 50 mg once daily in patients receiving concurrent strong CYP3A4 inducers. Monitor patients closely for evidence of toxicity or inadequate clinical response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fedratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felbamate: PHENobarbital may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of PHENobarbital.  Management: Initiate felbamate at typical doses (1,200 mg/day in 3 or 4 divided doses for adults and children 14 years of age or older; 15 mg/kg/day in 3 or 4 divided doses in children 2 to 14 years of age) while reducing the phenobarbital dose by 20%.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Felodipine.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced felodipine efficacy and the need for felodipine dose increases.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fenfluramine.  Management: Avoid concurrent use of strong CYP3A4 inducers with fenfluramine when possible. If combined use cannot be avoided, consider increasing the fenfluramine dose, but do not exceed the fenfluramine maximum daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: PHENobarbital may enhance the CNS depressant effect of FentaNYL. PHENobarbital may decrease the serum concentration of FentaNYL.  Management: Avoid use of fentanyl and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased fentanyl efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fesoterodine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Finerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Folic Acid: May decrease the serum concentration of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fosamprenavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosnetupitant: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fosnetupitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May enhance the CNS depressant effect of PHENobarbital. Fosphenytoin may increase the serum concentration of PHENobarbital. PHENobarbital may decrease the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostamatinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fostamatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostemsavir: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fostemsavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fruquintinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fruquintinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Futibatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganaxolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ganaxolone.  Management: Avoid concomitant use of ganaxolone and strong CYP3A4 inducers whenever possible. If combined, consider increasing the dose of ganaxolone, but do not exceed the maximum recommended daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse reactions, increase the gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers; resume 250 mg dose 7 days after discontinuation of the strong inducer. Carefully monitor clinical response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemigliptin: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Strong) may decrease the serum concentration of Gemigliptin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gepirone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gestrinone: PHENobarbital may decrease the serum concentration of Gestrinone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gilteritinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Glasdegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: Barbiturates may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Strong) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a strong CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: PHENobarbital may enhance the CNS depressant effect of HYDROcodone. PHENobarbital may decrease the serum concentration of HYDROcodone.  Management: Avoid use of hydrocodone and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased hydrocodone efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrexafungerp: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ibrexafungerp. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ibrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Idelalisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Idelalisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid use of imatinib and strong CYP3A4 inducers when possible. If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely. Doses up to 1200 mg/day (600 mg twice daily) have been used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Indinavir.  Management: Consider avoiding the combination of indinavir and strong CYP3A4 inducers whenever possible due to the risk for decreased indinavir concentrations, reduced efficacy, and development of resistance. If combined, monitor for indinavir treatment failure<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan Products.  Management: Avoid administration of strong CYP3A4 inducers during irinotecan treatment, and substitute non-CYP3A4 inducing agents at least 2 weeks prior to irinotecan initiation, whenever possible. If combined, monitor for reduced irinotecan efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Strong) may decrease isavuconazole serum concentrations. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Istradefylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Itraconazole. CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivosidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible. If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup> (given as a 4-hour infusion), as tolerated, should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixazomib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Ketoconazole (Systemic).  Management: The use of ketoconazole concurrently with or within 2 weeks of a strong CYP3A4 inducer is not recommended. If such a combination cannot be avoided, monitor patients closely for evidence of diminished clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lacidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: PHENobarbital may enhance the adverse/toxic effect of LamoTRIgine. Specifically, the risk for hematologic toxicities may be increased. PHENobarbital may decrease the serum concentration of LamoTRIgine.  Management: For patients taking phenobarbital without valproate, lamotrigine dose adjustments are recommended for lamotrigine initiation. Recommendations vary based on lamotrigine indication and age. See full interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If concomitant use cannot be avoided, titrate lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Larotrectinib.  Management: Avoid use of strong CYP3A4 inducers with larotrectinib. If this combination cannot be avoided, double the larotrectinib dose. Reduced to previous dose after stopping the inducer after a period of 3 to 5 times the inducer's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: PHENobarbital may decrease the serum concentration of Ledipasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with strong CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): CYP3A4 Inducers (Strong) may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin intravenous infusion with strong CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lenacapavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Leniolisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: UGT1A1 Inducers may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leucovorin Calcium-Levoleucovorin: May decrease the serum concentration of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leuprolide and Norethindrone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Leuprolide and Norethindrone. Specifically, norethindrone concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LevETIRAcetam: May enhance the CNS depressant effect of PHENobarbital. PHENobarbital may decrease the serum concentration of LevETIRAcetam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomefolate: May decrease the serum concentration of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: PHENobarbital may enhance the CNS depressant effect of Levomethadone. PHENobarbital may decrease the serum concentration of Levomethadone.  Management: Avoid concomitant use of levomethadone and phenobarbital when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonorgestrel (IUD): CYP3A4 Inducers (Strong) may diminish the therapeutic effect of Levonorgestrel (IUD). CYP3A4 Inducers (Strong) may decrease the serum concentration of Levonorgestrel (IUD). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: CYP3A4 Inducers (Strong) may decrease the serum concentration of LinaGLIPtin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: PHENobarbital may decrease the serum concentration of Lopinavir.  Management: Increased doses of lopinavir may be necessary when using these agents in combination.  Do not use a once daily lopinavir/ritonavir regimen together with phenobarbital. Increase monitoring of therapeutic response in all patients using this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: CYP3A4 Inducers (Strong) may enhance the hepatotoxic effect of Lorlatinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Lorlatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumacaftor and Ivacaftor. Specifically, the serum concentration of ivacaftor may be decreased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumateperone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurbinectedin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurbinectedin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Manidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Manidipine.  Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inducers. If combined, monitor closely for decreased manidipine effects and loss of efficacy. Increased manidipine doses may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice/day, but only if not receiving a strong CYP3A4 inhibitor. Not recommended for pediatric patients not also receiving a strong CYP3A4 inhibitor. Contraindicated in patients with CrCl less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: PHENobarbital may decrease the serum concentration of Maribavir.  Management: Increase the dose of maribavir to 1,200 mg twice daily with concomitant use of phenobarbital.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of PHENobarbital. PHENobarbital may decrease the serum concentration of Mefloquine. Mefloquine may decrease the serum concentration of PHENobarbital. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If phenobarbital is being used for another indication, monitor for decreased concentrations and efficacy of both phenobarbital and mefloquine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: PHENobarbital may enhance the CNS depressant effect of Meperidine. PHENobarbital may increase serum concentrations of the active metabolite(s) of Meperidine.  Management: Avoid concomitant use of meperidine and phenobarbital when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: PHENobarbital may enhance the CNS depressant effect of Methadone. PHENobarbital may decrease the serum concentration of Methadone.  Management: Avoid concomitant use of methadone and phenobarbital when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, a disulfiram-like reaction may occur and CNS depressant effects may be increased.  Management: Avoid products containing alcohol in patients treated with methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: Barbiturates may enhance the nephrotoxic effect of Methoxyflurane. Barbiturates may increase the metabolism of Methoxyflurane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylergonovine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Methylergonovine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylfolate: May decrease the serum concentration of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May increase the serum concentration of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of PHENobarbital. A disulfiram-like reaction may occur if combined with phenobarbital dosage forms that contain propylene glycol or alcohol. PHENobarbital may decrease the serum concentration of MetroNIDAZOLE (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the CNS depressant effect of Barbiturates. Mianserin may diminish the therapeutic effect of Barbiturates. Barbiturates may decrease the serum concentration of Mianserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Midostaurin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MiFEPRIStone.  Management: Avoid combined use in patients treated for Cushing's disease. When used for pregnancy termination, mifepristone efficacy may be reduced and an alternative pregnancy termination procedure may be warranted. Ensure a follow-up assessment after combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirodenafil.  Management: Consider avoiding the concomitant use of mirodenafil and strong CYP3A4 inducers. If combined, monitor for decreased mirodenafil effects. Mirodenafil dose increases may be required to achieve desired effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirtazapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mitapivat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Mobocertinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naldemedine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nateglinide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nateglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nelfinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netupitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Netupitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nevirapine.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced nevirapine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiCARdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NiCARdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Avoid coadministration of nifedipine with strong CYP3A4 inducers when possible and if combined, monitor patients closely for clinical signs of diminished nifedipine response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilvadipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilvadipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NiMODipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nintedanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of PHENobarbital. PHENobarbital may decrease the serum concentration of Nirmatrelvir and Ritonavir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrazepam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nitrazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: CYP1A2 Inducers (Weak) may decrease the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olutasidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Omaveloxolone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ondansetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: PHENobarbital may decrease the serum concentration of Ornidazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osilodrostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osilodrostat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osimertinib.  Management: Avoid coadministration of osimertinib and strong CYP3A4 inducers if possible. If coadministration is unavoidable, increase osimertinib to 160 mg daily. Reduce osimertinib to 80 mg daily 3 weeks after discontinuation of the strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: CYP3A4 Inducers (Strong) may decrease the serum concentration of OXcarbazepine. Specifically, the concentrations of the 10-monohydroxy active metabolite of oxcarbazepine may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: PHENobarbital may enhance the CNS depressant effect of OxyCODONE. PHENobarbital may decrease the serum concentration of OxyCODONE.  Management: Avoid use of oxycodone and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased oxycodone efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inducers (Strong) may decrease the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Palbociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Palovarotene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pemigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Increase perampanel starting dose to 4 mg/day if used  with strong CYP3A4 inducers. Increase perampanel dose by 2 mg/day no more than once weekly based on response and tolerability. Dose adjustments may be needed if the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pexidartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: May enhance the CNS depressant effect of PHENobarbital. PHENobarbital may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pimavanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Piperaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pirtobrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pitolisant.  Management: If on a stable pitolisant dose of 8.9 mg or 17.8 mg/day and starting a strong CYP3A4 inducer, double the pitolisant dose over 7 days (ie, to either 17.8 mg/day or 35.6 mg/day, respectively). Reduce pitolisant dose by 50% when the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polatuzumab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Polatuzumab Vedotin. Exposure to unconjugated MMAE, the cytotoxic small molecule component of polatuzumab vedotin, may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib.  Management: Avoid coadministration of ponatinib with strong CYP3A4 inducers unless the potential benefit of concomitant treatment outweighs the risk of reduced ponatinib exposure. Monitor patients for reduced ponatinib efficacy if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: UGT1A1 Inducers may decrease the serum concentration of Ponesimod. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pralsetinib.  Management: Avoid concomitant use of pralsetinib with strong CYP3A4 inducers when possible. If combined, increase the starting dose of pralsetinib to double the current pralsetinib dosage starting on day 7 of coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pretomanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: PHENobarbital may increase the metabolism of Propacetamol. Specifically, formation of the hepatotoxic NAPQI metabolite may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pyridoxine: May decrease the serum concentration of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of QUEtiapine.  Management: An increase in quetiapine dose (as much as 5 times the regular dose) may be required to maintain therapeutic benefit. Reduce the quetiapine dose back to the previous/regular dose within 7 to 14 days of discontinuing the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inducers (Strong) may decrease the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: May increase the serum concentration of PHENobarbital. PHENobarbital may decrease the serum concentration of QuiNINE. Management: Consider alternatives to this combination when possible. If coadministration of phenobarbital and quinine cannot be avoided, monitor for reduced quinine efficacy and for increased phenobarbital serum concentrations and toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Quizartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Radotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Radotinib.  Management: Consider alternatives to this combination when possible as the risk of radotinib treatment failure may be increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Reboxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ribociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rifabutin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: PHENobarbital may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rimegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ripretinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ripretinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of RisperiDONE. CYP3A4 Inducers (Strong) may decrease the serum concentration of RisperiDONE.  Management: Careful monitoring for reduced risperidone efficacy and possible dose adjustment are recommended when combined with strong CYP3A4 inducers. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease the serum concentration of PHENobarbital. PHENobarbital may decrease the serum concentration of Ritonavir. Management: Consider avoiding this combination due to the potential for decreased ritonavir concentrations and the possible development of resistance. If combined, monitor for decreased phenobarbital and ritonavir concentrations and effects during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.  Management: Consider alternatives to use of rivaroxaban with strong CYP3A4 inducers. Use of a strong CYP3A4 inducer with rivaroxaban should be strictly avoided in any patient who is using an agent (either the CYP3A4 inducer or a third drug) that induces P-gp.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast (Systemic): CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Roflumilast (Systemic). CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rolapitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May increase the serum concentration of PHENobarbital. PHENobarbital may decrease the serum concentration of Rufinamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ruxolitinib (Systemic). CYP3A4 Inducers (Strong) may decrease the serum concentration of Ruxolitinib (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sacituzumab Govitecan: UGT1A1 Inducers may decrease serum concentrations of the active metabolite(s) of Sacituzumab Govitecan. Specifically, concentrations of SN-38 may be decreased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Samidorphan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sapropterin: PHENobarbital may decrease the serum concentration of Sapropterin. Specifically, phenobarbital may decrease tissue concentrations of tetrahydrobiopterin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: PHENobarbital may decrease the serum concentration of Saquinavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SAXagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Ethanol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Propylene Glycol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Selpercatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Selumetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sertindole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sertraline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of Sirolimus (Conventional).  Management: Avoid concomitant use of strong CYP3A4 inducers and sirolimus if possible. If combined, monitor for reduced serum sirolimus concentrations. Sirolimus dose increases will likely be necessary to prevent subtherapeutic sirolimus levels.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Strong) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sofosbuvir: PHENobarbital may decrease the serum concentration of Sofosbuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Solifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sotorasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Stiripentol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Stiripentol.  Management: Avoid concomitant use of stiripentol and strong CYP3A4 inducers when possible. If combined, monitor for reduced stiripentol efficacy and increase the stiripentol dose as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: PHENobarbital may enhance the CNS depressant effect of SUFentanil. PHENobarbital may decrease the serum concentration of SUFentanil.  Management: Avoid use of sufentanil and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased sufentanil efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulthiame: May enhance the adverse/toxic effect of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If combined, increase sunitinib dose to a max of 87.5 mg daily when treating GIST or RCC. Increase sunitinib dose to a max of 62.5 mg daily when treating PNET. Monitor patients for both reduced efficacy and increased toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Tacrolimus (Systemic).  Management: Monitor for decreased tacrolimus concentrations and effects when combined with strong CYP3A4 inducers. Tacrolimus dose increases will likely be needed during concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction or benign prostatic hypertrophy: monitor for decreased effectiveness - no standard dose adjustment is recommended. Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Strong) may decrease the serum concentration of Tamoxifen. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tasimelteon. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Taurursodiol. Specifically, the concentrations of phenylbutyrate may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tazemetostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be decreased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Temsirolimus.  Management: Avoid concomitant use of temsirolimus and strong CYP3A4 inducers. If coadministration is unavoidable, increase temsirolimus dose to 50 mg per week. Resume previous temsirolimus dose after discontinuation of the strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Alafenamide: PHENobarbital may decrease the serum concentration of Tenofovir Alafenamide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol and Cannabidiol.  Management: Avoid use of the tetrahydrocannabinol/cannabidiol oromucosal spray and strong CYP3A4 inducers when possible. If combined use is necessary, careful titration is recommended, notably within the two weeks following discontinuation of the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tezacaftor and Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Strong) may decrease the serum concentration of Thiotepa.  Management: Thiotepa prescribing information recommends avoiding concomitant use of thiotepa and strong CYP3A4 inducers. If concomitant use is unavoidable, monitor for adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: PHENobarbital may decrease the serum concentration of Thiothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: PHENobarbital may decrease the serum concentration of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiaGABine: CYP3A4 Inducers (Strong) may decrease the serum concentration of TiaGABine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Timolol (Systemic): PHENobarbital may enhance the hypotensive effect of Timolol (Systemic). PHENobarbital may decrease the serum concentration of Timolol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: PHENobarbital may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tivozanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tivozanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Toremifene. CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: PHENobarbital may enhance the CNS depressant effect of TraMADol. PHENobarbital may decrease the serum concentration of TraMADol.  Management: Avoid use of tramadol and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased tramadol efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inducers (Strong) may decrease the serum concentration of TraZODone.  Management: Consider increasing the trazodone dose during coadministration with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamcinolone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Triamcinolone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Triazolam.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced triazolam efficacy. Substantial triazolam dose increases will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.  Management: Monitor for decreased efficacy of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. Tricyclic antidepressant dose adjustments are likely required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tropisetron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tropisetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tucatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tucatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ubrogepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Udenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Strong) may decrease the serum concentration of Valbenazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vandetanib: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Vandetanib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.  Management: Avoid coadministration of vemurafenib and strong CYP3A4 inducers if possible. If coadministration is unavoidable, increase the vemurafenib dose by 240 mg as tolerated. Resume prior vemurafenib dose 2 weeks after discontinuation of strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inducers (Strong) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Verapamil.  Management: Consider alternatives to this combination. If combined, monitor for reduced verapamil efficacy. Verapamil dose increases may be necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.  Management: Consider increasing vilazodone dose by as much as 2-fold (do not exceed 80 mg/day), based on response, in patients receiving strong CYP3A4 inducers for &gt; 14 days. Reduce to the original vilazodone dose over 1 to 2 weeks after inducer discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine: CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vinflunine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinorelbine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vinorelbine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.  Management: Monitor INR more closely. Anticoagulant dose increases of 30% to 60%  may be needed after a barbiturate is initiated or given at an increased dose. Anticoagulant dose decreases may be needed following barbiturate discontinuation or dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vonoprazan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vonoprazan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: PHENobarbital may decrease the serum concentration of Voriconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vortioxetine.  Management: Consider increasing the vortioxetine dose to no more than 3 times the original dose when used with a strong drug metabolism inducer for more than 14 days. The vortioxetine dose should be returned to normal within 14 days of stopping the strong inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxelotor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voxelotor.  Management: Avoid concomitant use of voxelotor and strong CYP3A4 inducers. If  unavoidable, increase the voxelotor dose to 2,500 mg once daily. For children ages 4 to less than 12 years, weight-based dose adjustments are required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zaleplon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zaleplon.  Management: Consider the use of an alternative hypnotic that is not metabolized by CYP3A4 in patients receiving strong CYP3A4 inducers. If zaleplon is combined with a strong CYP3A4 inducer, monitor for decreased effectiveness of zaleplon.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zanubrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ziprasidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zonisamide: May enhance the CNS depressant effect of PHENobarbital. PHENobarbital may decrease the serum concentration of Zonisamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: PHENobarbital may enhance the CNS depressant effect of Zopiclone. PHENobarbital may decrease the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuranolone. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F208953"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Phenobarbital increases the hepatic metabolism of vitamin D to inactive compounds and reduces calcium absorption (Gough 1986).  Management: Increase intake of foods rich in vitamin D. Supplementation of vitamin D and/or calcium may be necessary.</p></div>
<div class="block pri drugH1Div" id="F208939"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Phenobarbital crosses the placenta (Harden 2009b). Barbiturates can be detected in the placenta, fetal liver, and fetal brain. Fetal and maternal blood concentrations may be similar following parenteral administration. An increased incidence of fetal abnormalities may occur following maternal use. When used during the third trimester of pregnancy, withdrawal symptoms may occur in the neonate, including seizures and hyperirritability; symptoms of withdrawal may be delayed in the neonate up to 14 days after birth. Use during labor does not impair uterine activity; however, respiratory depression may occur in the newborn; resuscitation equipment should be available, especially for premature infants. Use for the treatment of epilepsy should be avoided during pregnancy (Harden 2009a).</p>
<p style="text-indent:0em;margin-top:2em;">A registry is available for women exposed to phenobarbital during pregnancy: Pregnant women may enroll themselves into the North American Antiepileptic Drug (AED) Pregnancy Registry (888-233-2334 or http://www.aedpregnancyregistry.org).</p></div>
<div class="block brc drugH1Div" id="F208940"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Phenobarbital is excreted in breast milk. A delayed interest in breast-feeding may occur in infants exposed in utero. Infantile spasms and other withdrawal symptoms have been reported following the abrupt discontinuation of breast-feeding (Knott 1987). The manufacturer recommends that caution be exercised when administering phenobarbital to nursing women.</p></div>
<div class="block dic drugH1Div" id="F208941"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Folate and vitamin B: Phenobarbital use has been associated with low serum concentrations of folate, vitamin B<sub>2</sub> (riboflavin), B<sub>6</sub> (pyridoxine) and B<sub>12</sub> (cyanocobalamin), which may contribute to hyperhomocysteinemia. Hyperhomocysteinemia may contribute to cardiovascular disease, venous thromboembolic disease, dementia, neuropsychiatric symptoms and poor seizure control. Some clinicians recommend administering folic acid, riboflavin, pyridoxine and cyanocobalamin supplements in patients taking phenobarbital (Apeland 2003; Apeland 2008; Belcastro 2012; Bochyńska 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D and calcium: Phenobarbital increases the hepatic metabolism of vitamin D to inactive compounds and reduces calcium absorption (Gough 1986); increase intake of foods rich in vitamin D. Supplementation of vitamin D and/or calcium may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F208924"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Phenobarbital serum concentrations (as clinically indicated); CNS status; liver enzymes (periodic); CBC with differential (periodic); renal function (periodic); seizure activity; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes); dermatological reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">IV use: Respiratory rate, heart rate, blood pressure; monitor infusion site.</p></div>
<div class="block rer drugH1Div" id="F208928"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Seizures:</p>
<p style="text-indent:-2em;margin-left:4em;">Timing of serum samples: Draw trough just before next dose (Hiemke 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Therapeutic reference range: A clear correlation between serum phenobarbital concentrations and therapeutic response has not been demonstrated; however, a range of 10 to 40 mcg/mL (SI: 43 to 172 micromole/L) has been reported (Patsalos 2018). In select clinical circumstances (eg, refractory status epilepticus, weaning pentobarbital), higher serum phenobarbital concentrations have been targeted in adults (Byun 2015; NCS [Brophy 2012]).</p>
<p style="text-indent:-2em;margin-left:4em;">Laboratory alert level: 50 mcg/mL (SI: 215 micromole/L) (Hiemke 2018).</p></div>
<div class="block pha drugH1Div" id="F208913"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Long-acting barbiturate with sedative, hypnotic, and antiseizure properties. Barbiturates depress the sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, and hypnosis. In high doses, barbiturates exhibit antiseizure activity; barbiturates produce dose-dependent respiratory depression.</p></div>
<div class="block phk drugH1Div" id="F208934"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: ≥60 minutes; IV: 5 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: IV: CNS depression: ≥15 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Oral: 10 to 12 hours; IV: &gt;6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Adults: Rapid and complete; Newborns: Delayed and incomplete (Patsalos 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: 0.85 ± 0.059 L/kg (Heimann 1977).</p>
<p style="text-indent:-2em;margin-left:4em;">2 to 3 months: 0.857 ± 0.089 L/kg (Heimann 1977).</p>
<p style="text-indent:-2em;margin-left:4em;">4 to 12 months: 0.57 ± 0.046 L/kg (Heimann 1977).</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 5 years: 0.666 ± 0.073 L/kg (Heimann 1977).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.61 L/kg (Patsalos 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and young infants: 36% to 43% (Patsalos 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 48% (Patsalos 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic by oxidation via CYP2C9 and to a lesser extent via CYP2C19 and CYP2E1, and by N-glucosidation (Patsalos 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and young infants: ~48.9 (Marsot 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 90% (Patsalos 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">≤10 days of life: 114.2 ± 43 hours (Alonso Gonzalez 1993; Patsalos 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">11 to 30 days of life: 73.19 ± 24.17 hours (Alonso Gonzalez 1993; Patsalos 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">2 to 3 months: 62.9 ± 5.2 hours (Heimann 1977).</p>
<p style="text-indent:-2em;margin-left:4em;">4 to 12 months: 63.2 ± 4.2 hours (Heimann 1977).</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 5 years: 68.5 ± 3.2 hours (Heimann 1977).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~79 hours (range: 53 to 118 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Newborns: 1.5 to 6 hours (Patsalos 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 2 to 4 hours (Patsalos 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (25% to 50% as unchanged drug); feces (minimal).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F208942"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Gardenal | Phenobarbitone | Pms phenobarbitone</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alepsal | Fada fenobarbital | Fenobarbital | Fenobarbital cevallos | Fenobarbital klonal | Fenros | Gardenal | Luminal | Luminaletas | Prudema</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Phenobarb | Phenobarb sodium | Phenobarbitone</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Barbit | Berdinal | Emer | Epinal | Gardenal | Phenoba | Phenobarbitone | Phenoson</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Gardenal | Luminal</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Luminal | Phenobarbital</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Barbitron | Carbital | Fenobarbital | Fenocris | Furp fenobarbital | Garbital | Gardenal | Unifenobarb</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Aphenylbarbit | Luminal | Phenobarbital Amino | Phenobarbital Galepharm | Phenobarbital wiedenmann</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Fenobarbital</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbital | Phenobarbitone</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Fenobarbital</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Phenaemal | Phenaemaletten</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lepinal | Luminal | Luminaletten | Phenobarbital Neuraxpharm</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Fenemal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dormital | Fenarbital | Fenobarbital</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fenobarbital</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Phenaemal | Phenaemaletten</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbitone | Sominal | Suminal | Suminalette</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Gardenal | Luminal | Luminaletas</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Barbital | Phenocar</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Barbilettae | Barbiphenyl</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Aparoxal | Gardenal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Gardenal | Parabal | Phenobarbitone | Phenobarbitone cox | Phenobarbitone dc | Phenobr sodium</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Gardenal</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbitone | Uni-Feno</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbiton Pliva</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Sevenal | Sevenaletta</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Luminal | Phenobarbital | Phental | Sibital</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbitone</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alphen | Barbee | Barbitoin | Emgard | Epinil | Epitan | Fenobarb | Luminal | Luminalettes | Phenetone | Phenobarb | Phenobarbitone</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Luminal 30 kindi</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Gardenale | Luminale | Luminalette</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbitone | Phenotal</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Balphenyl | Phenobal | Phenobarbital</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Phenbital | Phenobarb | Phenobarbitone | Phental</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Daewon phenobarbital | Hana phenobarbital | Phenobarbital</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Gardenal | Lactocalm</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dormiral | Hysteps | Luminal | Luminalettes | Phenaema letten | Phenaenal | Phenobarbital</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Gardenal</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dormiral | Hysteps | Luminal | Luminalettes | Luminalum | Phenaenal | Phenobarbital | Phenobarbitalum</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Gardenal</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alepsal | Bitalpera | Eurobil | Fenabbott | Fenobarbital | Fenocriz | Sevenal chinoin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbitone</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fenobarbital</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aphenylbarbit | Fenemal | Fenemal Naf | Fenobarbital</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbitone</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Fenobarbital</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbital Rhea | Rhea phenobarbital</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aleptal | Barbi | Debritone | Fenton | Pbtone | Phenobar | Phenobarbitone | Phenotab | Phenotone</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dormiral | Lumidrinal | Luminalum | Phenobarbital</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Luminal | Phenobarbital elixir</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bialminal | Luminal | Luminaletas</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Barbinal | Dormital | Dormitaletas</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Fenobarbital arena | Fenobarbital zentiva | Gardenal</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbital</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Gardenal | Phenobarbitone</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fenemal recip</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbitone</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbiton</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Phenaemal | Phenaemaletten</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Verbital</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Gardenal sodium | Menobarb | Phenobarb | Phenobarbitone | Phenoco | Phenosil | Phenotal</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Bialminal | Gardenal</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Luminal | Luminaletten</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">L.A | Phenobarbital | Phenobital | Rumil</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbital | Phenobarbiton | Phenobarbitone</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">B tone | Phenbital | Phenobarbitone</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Drimy | Farmacoletas | Farmaconal | Fenobarbital | Gardenal | Gardenaletas</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fenobarbital | Gardenal</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Gardenal | Garnotal</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Gardenal | Lethyl | Sedabarb</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbitone</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Phenobarbitone</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8227234">
<a name="8227234"></a>Alonso Gonzalez AC, Ortega Valin L, Santos Buelga D, et al. Dosage programming of phenobarbital in neonatal seizures. <i>J Clin Pharm Ther</i>. 1993;18(4):267-270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/8227234/pubmed" id="8227234" target="_blank">8227234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32511109">
<a name="32511109"></a>American Society of Addiction Medicine (ASAM). The ASAM clinical practice guideline on alcohol withdrawal management. <i>J Addict Med</i>. 2020:14(3S)(suppl 1):1-72. doi:10.1097/ADM.0000000000000668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/32511109/pubmed" id="32511109" target="_blank">32511109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18644700">
<a name="18644700"></a>Apeland T, Frøyland ES, Kristensen O, Strandjord RE, Mansoor MA. Drug-induced pertubation of the aminothiol redox-status in patients with epilepsy: improvement by B-vitamins. <i>Epilepsy Res</i>. 2008;82(1):1-6. doi:10.1016/j.eplepsyres.2008.06.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/18644700/pubmed" id="18644700" target="_blank">18644700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12766014">
<a name="12766014"></a>Apeland T, Mansoor MA, Pentieva K, McNulty H, Strandjord RE. Fasting and post-methionine loading concentrations of homocysteine, vitamin B2, and vitamin B6 in patients on antiepileptic drugs. <i>Clin Chem</i>. 2003;49(6, pt 1):1005-1008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/12766014/pubmed" id="12766014" target="_blank">12766014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818889">
<a name="20818889"></a>Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. <i>N Engl J Med</i>. 2010;363(6):542-551. doi:10.1056/NEJMoa0909801<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/20818889/pubmed" id="20818889" target="_blank">20818889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19010446">
<a name="19010446"></a>Arif H, Buchsbaum R, Weintraub D, Pierro J, Resor SR Jr, Hirsch LJ. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. <i>Epilepsy Behav</i>. 2009;14(1):202-209. doi:10.1016/j.yebeh.2008.10.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/19010446/pubmed" id="19010446" target="_blank">19010446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24365310">
<a name="24365310"></a>Asconapé JJ. Use of antiepileptic drugs in hepatic and renal disease. <i>Handb Clin Neurol</i>. 2014;119:417-432.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/24365310/pubmed" id="24365310" target="_blank">24365310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1562334">
<a name="1562334"></a>Audenaert SM, Lock RL, Johnson GL, Pedigo NW Jr. Cardiovascular effects of rectal methohexital in children. <i>J Clin Anesth</i>. 1992;4(2):116-119. doi:10.1016/0952-8180(92)90026-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/1562334/pubmed" id="1562334" target="_blank">1562334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12897635">
<a name="12897635"></a>Baruzzi A, Contin M, Barbara G, et al. Drug rash with eosinophilia and systemic symptoms secondary to phenobarbitone. <i>Clin Neuropharmacol</i>. 2003;26(4):177-178. doi:10.1097/00002826-200307000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/12897635/pubmed" id="12897635" target="_blank">12897635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15304627">
<a name="15304627"></a>Bavdekar SB, Muranjan MN, Gogtay NJ, Kantharia V, Kshirsagar NA. Anticonvulsant hypersensitivity syndrome: lymphocyte toxicity assay for the confirmation of diagnosis and risk assessment. <i>Ann Pharmacother</i>. 2004;38(10):1648-1650. doi:10.1345/aph.1E042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/15304627/pubmed" id="15304627" target="_blank">15304627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22824326">
<a name="22824326"></a>Belcastro V, Striano P. Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy. <i>Epilepsy Res</i>. 2012;102(1-2):1-7. doi:10.1016/j.eplepsyres.2012.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/22824326/pubmed" id="22824326" target="_blank">22824326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19453718">
<a name="19453718"></a>Bell GS, Gaitatzis A, Bell CL, Johnson AL, Sander JW. Suicide in people with epilepsy: how great is the risk? <i>Epilepsia</i>. 2009;50(8):1933-1942. doi:10.1111/j.1528-1167.2009.02106.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/19453718/pubmed" id="19453718" target="_blank">19453718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28190254">
<a name="28190254"></a>Bellivier F, Belzeaux R, Scott J, Courtet P, Golmard JL, Azorin JM. Anticonvulsants and suicide attempts in bipolar I disorders. <i>Acta Psychiatr Scand</i>. 2017;135(5):470-478. doi:10.1111/acps.12709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/28190254/pubmed" id="28190254" target="_blank">28190254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30955419">
<a name="30955419"></a>Bermeo-Ovalle A. Making rash decisions in epilepsy: evaluating hypersensitivity reactions to anti-seizure medications. <i>Epilepsy Curr</i>. 2019;19(2):96-98. doi:10.1177/1535759719835672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/30955419/pubmed" id="30955419" target="_blank">30955419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11346057">
<a name="11346057"></a>Bessmertny O, Hatton RC, Gonzalez-Peralta RP. Antiepileptic hypersensitivity syndrome in children. <i>Ann Pharmacother</i>. 2001;35(5):533-538. doi:10.1345/aph.10284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/11346057/pubmed" id="11346057" target="_blank">11346057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25933949">
<a name="25933949"></a>Błaszczyk B, Lasoń W, Czuczwar SJ. Antiepileptic drugs and adverse skin reactions: An update. <i>Pharmacol Rep</i>. 2015;67(3):426-434. doi:10.1016/j.pharep.2014.11.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/25933949/pubmed" id="25933949" target="_blank">25933949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22360846">
<a name="22360846"></a>Bochyńska A, Lipczyńska-Łojkowska W, Gugała-Iwaniuk M, et al. The effect of vitamin B supplementation on homocysteine metabolism and clinical state of patients with chronic epilepsy treated with carbamazepine and valproic acid. <i>Seizure</i>. 2012;21(4):276-281. doi:10.1016/j.seizure.2012.01.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/22360846/pubmed" id="22360846" target="_blank">22360846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17896897">
<a name="17896897"></a>Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. <i>Pharmacotherapy</i>. 2007;27(10):1425-1439. doi:10.1592/phco.27.10.1425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/17896897/pubmed" id="17896897" target="_blank">17896897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8784213">
<a name="8784213"></a>Bourgeois BF. Antiepileptic drugs in pediatric practice. <i>Epilepsia</i>. 1995;36(suppl 2):S34-S45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/8784213/pubmed" id="8784213" target="_blank">8784213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2339032">
<a name="2339032"></a>Brent DA, Crumrine PK, Varma R, Brown RV, Allan MJ. Phenobarbital treatment and major depressive disorder in children with epilepsy: a naturalistic follow-up. <i>Pediatrics</i>. 1990;85(6):1086-1091.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/2339032/pubmed" id="2339032" target="_blank">2339032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528274">
<a name="22528274"></a>Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23. doi:10.1007/s12028-012-9695-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/22528274/pubmed" id="22528274" target="_blank">22528274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Burgos.1">
<a name="Burgos.1"></a>Burgos AE. Burke, Jr BL. Neonatal abstinence syndrome.<i> Neoreviews</i>. 2009;10(5):222-229.</div>
</li>
<li>
<div class="reference">
                  Byun JI, Chu K, Sunwoo JS, et al. Mega-dose phenobarbital therapy for super-refractory status epilepticus. <i>Epileptic Disord</i>. 2015;17(4):444-452. doi:10.1684/epd.2015.0778<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/26575689/pubmed" id="26575689" target="_blank">26575689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2220307">
<a name="2220307"></a>Calandre EP, Dominguez-Granados R, Gomez-Rubio M, Molina-Font JA. Cognitive effects of long-term treatment with phenobarbital and valproic acid in school children. <i>Acta Neurol Scand</i>. 1990;81(6):504-506. doi:10.1111/j.1600-0404.1990.tb01008.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/2220307/pubmed" id="2220307" target="_blank">2220307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24659126">
<a name="24659126"></a>Chadly Z, Aouam K, Chaabane A, Belhadjali H, Abderrazzak Boughattas N, Zili JE. A patch test confirmed phenobarbital-induced fixed drug eruption in a child. <i>Iran J Allergy Asthma Immunol</i>. 2014;13(3):214-217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/24659126/pubmed" id="24659126" target="_blank">24659126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14505048">
<a name="14505048"></a>Chen CJ, Huang YC, Wang CY, Lin TY. Fatal anticonvulsant hypersensitivity syndrome in an infant. <i>Eur J Pediatr</i>. 2003;162(12):893-894. doi:10.1007/s00431-003-1190-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/14505048/pubmed" id="14505048" target="_blank">14505048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17519457">
<a name="17519457"></a>Cies JJ, Giamalis JN. Treatment of Cholestatic Pruritus in Children. <i>Am J Health Syst Pharm</i>. 2007;64(11):1157-1162.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/17519457/pubmed" id="17519457" target="_blank">17519457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2630236">
<a name="2630236"></a>De Carolis MP, Muzii U, Romagnoli C, Zuppa AA, Zecca E, Tortorolo G. Phenobarbital for treatment of seizures in preterm infant: a new administration scheme. <i>Dev Pharmacol Ther</i>. 1989;14(2):84-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/2630236/pubmed" id="2630236" target="_blank">2630236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Domonoske.1">
<a name="Domonoske.1"></a>Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th edition. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31191808">
<a name="31191808"></a>Doshi AR, Malhotra MG, Balaguru D, Amre D, Erikson C. Effect of intravenous phenobarbital on left ventricular myocardial contractility determined by echocardiography in children. <i>Kans J Med</i>. 2019;12(2):40-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/31191808/pubmed" id="31191808" target="_blank">31191808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10071329">
<a name="10071329"></a>Duncan KO, Tigelaar RE, Bolognia JL. Stevens-Johnson syndrome limited to multiple sites of radiation therapy in a patient receiving phenobarbital. <i>J Am Acad Dermatol</i>. 1999;40(3):493-496. doi:10.1016/s0190-9622(99)70508-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/10071329/pubmed" id="10071329" target="_blank">10071329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7947221">
<a name="7947221"></a>Errani A, Reggiani M, Schianchi S, Staffa M. Toxic epidermal necrolysis induced by barbiturates and radiotherapy. <i>Br J Dermatol</i>. 1994;131(4):586-587. doi:10.1111/j.1365-2133.1994.tb08571.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/7947221/pubmed" id="7947221" target="_blank">7947221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23340399">
<a name="23340399"></a>Fabbrocini G, Panariello L, Pensabene M, et al. EMPACT syndrome associated with phenobarbital. <i>Dermatitis</i>. 2013;24(1):37-39. doi:10.1097/DER.0b013e31827ede32<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/23340399/pubmed" id="23340399" target="_blank">23340399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2242106">
<a name="2242106"></a>Farwell JR, Lee YJ, Hirtz DG, Sulzbacher SI, Ellenberg JH, Nelson KB. Phenobarbital for febrile seizures--effects on intelligence and on seizure recurrence.<i> N Engl J Med</i>. 1990;322(6):364-369. doi:10.1056/NEJM199002083220604<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/2242106/pubmed" id="2242106" target="_blank">2242106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-121340">
<a name="121340"></a>Finnegan LP, Mitros TF, Hopkins LE. Management of Neonatal Narcotic Abstinence Utilizing a Phenobarbital Loading Dose Method. <i>NIDA Res Monogr</i>. 1979;27:247-253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/121340/pubmed" id="121340" target="_blank">121340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31708349">
<a name="31708349"></a>Fowler T, Bansal AS, Lozsádi D. Risks and management of antiepileptic drug induced skin reactions in the adult out-patient setting. <i>Seizure</i>. 2019;72:61-70. doi:10.1016/j.seizure.2019.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/31708349/pubmed" id="31708349" target="_blank">31708349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12112085">
<a name="12112085"></a>Fujino Y, Nakajima M, Inoue H, Kusuhara T, Yamada T. Human herpesvirus 6 encephalitis associated with hypersensitivity syndrome. <i>Ann Neurol</i>. 2002;51(6):771-774. doi:10.1002/ana.10194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/12112085/pubmed" id="12112085" target="_blank">12112085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23673774">
<a name="23673774"></a>Gaitatzis A, Sander JW. The long-term safety of antiepileptic drugs. <i>CNS Drugs</i>. 2013;27(6):435-455. doi:10.1007/s40263-013-0063-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/23673774/pubmed" id="23673774" target="_blank">23673774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1750433">
<a name="1750433"></a>Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP. Familial occurrence of hypersensitivity to phenytoin. <i>Am J Med</i>. 1991;91(6):631-634. doi:10.1016/0002-9343(91)90216-k<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/1750433/pubmed" id="1750433" target="_blank">1750433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473127">
<a name="16473127"></a>Geurinni. Epilepsy in children. <i>Lancet</i>. 2006;367(9509):499-524.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/16473127/pubmed" id="16473127" target="_blank">16473127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2717283">
<a name="2717283"></a>Gilman JT, Gal P, Duchowny MS, et al. Rapid Sequential Phenobarbital Treatment of Neonatal Seizures. <i>Pediatrics</i>. 1989;83(5):674-678.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/2717283/pubmed" id="2717283" target="_blank">2717283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26900382">
<a name="26900382"></a>Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/26900382/pubmed" id="26900382" target="_blank">26900382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3092278">
<a name="3092278"></a>Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan N. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. <i>Q J Med</i>. 1986;59(230):569-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/3092278/pubmed" id="3092278" target="_blank">3092278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23683707">
<a name="23683707"></a>Greenfield LJ Jr. Molecular mechanisms of antiseizure drug activity at GABAA receptors. <i>Seizure</i>. 2013;22(8):589-600. doi:10.1016/j.seizure.2013.04.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/23683707/pubmed" id="23683707" target="_blank">23683707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29501520">
<a name="29501520"></a>Guvenir H, Dibek Misirlioglu E, Civelek E, et al. The frequency and clinical features of hypersensitivity reactions to antiepileptic drugs in children: a prospective study. <i>J Allergy Clin Immunol Pract</i>. 2018;6(6):2043-2050. doi:10.1016/j.jaip.2018.02.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/29501520/pubmed" id="29501520" target="_blank">29501520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4335442">
<a name="4335442"></a>Hahn TJ, Birge SJ, Scharp CR, Avioli LV. Phenobarbital-induced alterations in vitamin D metabolism. <i>J Clin Invest</i>. 1972;51(4):741-748. doi:10.1172/JCI106868<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/4335442/pubmed" id="4335442" target="_blank">4335442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9506654">
<a name="9506654"></a>Hall RT, Hall FK, Daily DK. High-Dose Phenobarbital Therapy in Term Newborn Infants With Severe Perinatal Asphyxia: A Randomized, Prospective Study With Three-Year Follow-Up. <i>J Pediatr</i>. 1998;132(2):345-348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/9506654/pubmed" id="9506654" target="_blank">9506654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398681">
<a name="19398681"></a>Harden CL, Meador KJ, Pennell PB, et al; American Academy of Neurology; American Epilepsy Society. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology</i>. 2009a;73(2):133-141. doi:10.1212/WNL.0b013e3181a6b312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/19398681/pubmed" id="19398681" target="_blank">19398681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398680">
<a name="19398680"></a>Harden CL, Pennell PB, Koppel BS, et al; American Academy of Neurology; American Epilepsy Society. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology</i>. 2009b;73(2):142-149. doi:10.1212/WNL.0b013e3181a6b325<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/19398680/pubmed" id="19398680" target="_blank">19398680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-590316">
<a name="590316"></a>Heimann G, Gladtke E. Pharmacokinetics of phenobarbital in childhood. <i>Eur J Clin Pharmacol</i>. 1977;12(4):305-310.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/590316/pubmed" id="590316" target="_blank">590316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20825805">
<a name="20825805"></a>Hendey GW, Dery RA, Barnes RL, Snowden B, Mentler P. A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal. <i>Am J Emerg Med</i>. 2011;29(4):382-385. doi:10.1016/j.ajem.2009.10.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/20825805/pubmed" id="20825805" target="_blank">20825805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19496806">
<a name="19496806"></a>Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: fire or false alarm? <i>Epilepsia</i>. 2009;50(5):978-986. doi:10.1111/j.1528-1167.2009.02012.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/19496806/pubmed" id="19496806" target="_blank">19496806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi 10.1055/s-0043-116492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30159873">
<a name="30159873"></a>Hocker S, Clark S, Britton J. Parenteral phenobarbital in status epilepticus revisited: Mayo Clinic experience. <i>Epilepsia</i>. 2018;59(suppl 2):193-197. doi:10.1111/epi.14488<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/30159873/pubmed" id="30159873" target="_blank">30159873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hoffman.1">
<a name="Hoffman.1"></a>Hoffman RS, Weinhouse GL. Management of moderate and severe alcohol withdrawal syndromes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30689189">
<a name="30689189"></a>Hosohata K, Inada A, Oyama S, Niinomi I, Wakabayashi T, Iwanaga K. Adverse cutaneous drug reactions associated with old- and new- generation antiepileptic drugs using the Japanese Pharmacovigilance Database. <i>Clin Drug Investig</i>. 2019;39(4):363-368. doi:10.1007/s40261-019-00754-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/30689189/pubmed" id="30689189" target="_blank">30689189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19811415">
<a name="19811415"></a>Huang YL, Hsieh MY, Hsiao PF, et al. Alopecia areata universalis after phenobarbital-induced anti-convulsant hypersensitivity syndrome. <i>Immunol Invest</i>. 2009;38(5):383-397. doi:10.1080/08820130902896824<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/19811415/pubmed" id="19811415" target="_blank">19811415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18760938">
<a name="18760938"></a>Huber B, Bocchicchio M, Hauser I, et al. Ambiguous results of an attempt to withdraw barbiturates in epilepsy patients with intellectual disability. <i>Seizure</i>. 2009;18(2):109-118. doi:10.1016/j.seizure.2008.07.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/18760938/pubmed" id="18760938" target="_blank">18760938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22291123">
<a name="22291123"></a>Hudak ML, Tan RC. Committee On Drugs, et al. Neonatal Drug Withdrawal. <i>Pediatrics</i>. 2012;129(2):e540-e560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/22291123/pubmed" id="22291123" target="_blank">22291123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6424397">
<a name="6424397"></a>Iivanainen M, Savolainen H. Side effects of phenobarbital and phenytoin during long-term treatment of epilepsy. <i>Acta Neurol Scand Suppl</i>. 1983;97:49-67. doi:10.1111/j.1600-0404.1983.tb01535.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/6424397/pubmed" id="6424397" target="_blank">6424397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network. Standard concentrations of neonatal drug infusions. 2011. https://www.ismp.org/Tools/PediatricConcentrations.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16970741">
<a name="16970741"></a>Israni RK, Kasbekar N, Haynes K, Berns JS. Use of antiepileptic drugs in patients with kidney disease. <i>Semin Dial</i>. 2006;19(5):408-416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/16970741/pubmed" id="16970741" target="_blank">16970741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32100469">
<a name="32100469"></a>Jha S, Basnet A, Ranjan Kumar R, et al. Phenobarbital rheumatism-A fresh look at an old malady: Case report and systematic review of literature. <i>Int J Rheum Dis</i>. 2020;23(4):589-594. doi:10.1111/1756-185X.13813<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/32100469/pubmed" id="32100469" target="_blank">32100469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22285834">
<a name="22285834"></a>Kawasaki SS, Jacapraro JS, Rastegar DA. Safety and effectiveness of a fixed-dose phenobarbital protocol for inpatient benzodiazepine detoxification. <i>J Subst Abuse Treat</i>. 2012;43(3):331-334. doi:10.1016/j.jsat.2011.12.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/22285834/pubmed" id="22285834" target="_blank">22285834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31997613">
<a name="31997613"></a>Kim HK, Kim DY, Bae EK, Kim DW. Adverse skin reactions with antiepileptic drugs using Korea Adverse Event Reporting System Database, 2008-2017. <i>J Korean Med Sci</i>. 2020;35(4):e17. doi:10.3346/jkms.2020.35.e17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/31997613/pubmed" id="31997613" target="_blank">31997613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2886736">
<a name="2886736"></a>Knott C, Reynolds F, Clayden G. Infantile Spasms on Weaning From Breast Milk Containing Anticonvulsants. <i>Lancet</i>. 1987;2(8553):272-273.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/2886736/pubmed" id="2886736" target="_blank">2886736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22794330">
<a name="22794330"></a>Knowles SR, Dewhurst N, Shear NH. Anticonvulsant hypersensitivity syndrome: an update. <i>Expert Opin Drug Saf</i>. 2012;11(5):767-778. doi:10.1517/14740338.2012.705828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/22794330/pubmed" id="22794330" target="_blank">22794330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15329080">
<a name="15329080"></a>Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. <i>Epilepsia</i>. 2004;45(9):1141-1149. doi:10.1111/j.0013-9580.2004.12704.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/15329080/pubmed" id="15329080" target="_blank">15329080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30070375">
<a name="30070375"></a>Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2019;69(1):394-419.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/30070375/pubmed" id="30070375" target="_blank">30070375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-574197">
<a name="574197"></a>Lockman LA, Kriel R, Zaske D, et al. Phenobarbital Dosage for Control of Neonatal Seizures. <i>Neurology</i>. 1979;29(11):1445-149.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/574197/pubmed" id="574197" target="_blank">574197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24051577">
<a name="24051577"></a>Maitre NL, Smolinsky C, Slaughter JC, Stark AR. Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. <i>J Perinatol</i>. 2013;33(11):841-846.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/24051577/pubmed" id="24051577" target="_blank">24051577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22326977">
<a name="22326977"></a>Malamiri RA, Ghaempanah M, Khosroshahi N, Nikkhah A, Bavarian B, Ashrafi MR. Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. <i>Eur J Paediatr Neurol</i>. 2012;16(5):536-541. doi:10.1016/j.ejpn.2012.01.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/22326977/pubmed" id="22326977" target="_blank">22326977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20064188">
<a name="20064188"></a>Mamishi S, Fattahi F, Pourpak Z, et al. Severe cutaneous reactions caused by barbiturates in seven Iranian children. <i>Int J Dermatol</i>. 2009;48(11):1254-1261. doi:10.1111/j.1365-4632.2007.03561.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/20064188/pubmed" id="20064188" target="_blank">20064188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27554620">
<a name="27554620"></a>Manuyakorn W, Mahasirimongkol S, Likkasittipan P, et al. Association of HLA genotypes with phenobarbital hypersensitivity in children. <i>Epilepsia</i>. 2016;57(10):1610-1616. doi:10.1111/epi.13509<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/27554620/pubmed" id="27554620" target="_blank">27554620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23855753">
<a name="23855753"></a>Marsot A, Brevaut-Malaty V, Vialet R, Boulamery A, Bruguerolle B, Simon N. Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach. <i>Fundam Clin Pharmacol</i>. 2014;28(4):465-471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/23855753/pubmed" id="23855753" target="_blank">23855753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2314578">
<a name="2314578"></a>Meador KJ, Loring DW, Huh K, Gallagher BB, King DW. Comparative cognitive effects of anticonvulsants. <i>Neurology</i>. 1990;40(3 pt 1):391-394. doi:10.1212/wnl.40.3_part_1.391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/2314578/pubmed" id="2314578" target="_blank">2314578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18676559">
<a name="18676559"></a>Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M, Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. <i>Pediatrics</i>. 2008;122(2):398-417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/18676559/pubmed" id="18676559" target="_blank">18676559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15824335">
<a name="15824335"></a>Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. <i>Neurology</i>. 2005;64(7):1134-1138. doi:10.1212/01.WNL.0000156354.20227.F0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/15824335/pubmed" id="15824335" target="_blank">15824335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29897629">
<a name="29897629"></a>Moffett BS, Weingarten MM, Galati M, et al. Phenobarbital population pharmacokinetics across the pediatric age spectrum. <i>Epilepsia</i>. 2018;59(7):1327-1333. doi:10.1111/epi.14447<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/29897629/pubmed" id="29897629" target="_blank">29897629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22994856">
<a name="22994856"></a>Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. <i>Epilepsia</i>. 2013;54(1):199-203. doi:10.1111/j.1528-1167.2012.03688.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/22994856/pubmed" id="22994856" target="_blank">22994856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Murphy.1">
<a name="Murphy.1"></a>Murphy JE. <i>Clinical Pharmacokinetics</i>. 4th ed. American Society of Health-System Pharmacists; 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32245300">
<a name="32245300"></a>Nafei Z, Behniafard N, Shefai F. Antiepileptic hypersensitivity syndrome to phenobarbital: a case report. <i>Iran J Allergy Asthma Immunol</i>. 2019;18(5):567-571. doi:10.18502/ijaai.v18i5.1926<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/32245300/pubmed" id="32245300" target="_blank">32245300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3953601">
<a name="3953601"></a>Nahata MC, Hipple TF, Strausbaugh SD. Stability of phenobarbital sodium diluted in 0.9% sodium chloride injection. <i>Am J Hosp Pharm</i>. 1986;43(2):384-385.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/3953601/pubmed" id="3953601" target="_blank">3953601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Published September 3, 2014. Accessed July 6, 2022. https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1996">
<a name="Nelson.1996"></a>Nelson WE, Behrman RE, Arvin AM, Kliegman RM, eds. Nelson Textbook of Pediatrics. 15th ed. Philadelphia, PA: WB Saunders Company; 1996: 2058-2078.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9614425">
<a name="9614425"></a>Neonatal drug withdrawal. American Academy of Pediatrics Committee on Drugs [published correction appears in <i>Pediatrics.</i> 1998;102(3, pt 1):660]. <i>Pediatrics</i>. 1998;101(6):1079-1088.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/9614425/pubmed" id="9614425" target="_blank">9614425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30876654">
<a name="30876654"></a>Nisavic M, Nejad SH, Isenberg BM, et al. Use of phenobarbital in alcohol withdrawal management - a retrospective comparison study of phenobarbital and benzodiazepines for acute alcohol withdrawal management in general medical patients. <i>Psychosomatics</i>. 2019;60(5):458-467. doi:10.1016/j.psym.2019.02.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/30876654/pubmed" id="30876654" target="_blank">30876654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29925291">
<a name="29925291"></a>Oks M, Cleven KL, Healy L, et al. The safety and utility of phenobarbital use for the treatment of severe alcohol withdrawal syndrome in the medical intensive care unit. <i>J Intensive Care Med</i>. 2020;35(9):844-850. doi:10.1177/0885066618783947<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/29925291/pubmed" id="29925291" target="_blank">29925291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26221907">
<a name="26221907"></a>Ordoñez L, Salgueiro E, Jimeno FJ, Manso G. Spontaneous reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with antiepileptic drugs. <i>Eur Rev Med Pharmacol Sci</i>. 2015;19(14):2732-2737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/26221907/pubmed" id="26221907" target="_blank">26221907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-621616">
<a name="621616"></a>Painter MJ, Pippenger C, MacDonald H, et al. Phenobarbital and Diphenylhydantoin Levels in Neonates With Seizures. <i>J Pediatr</i>. 1978;92(2):315-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/621616/pubmed" id="621616" target="_blank">621616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7196530">
<a name="7196530"></a>Painter MJ, Pippenger C, Wasterlain C, et al. Phenobarbital and Phenytoin in Neonatal Seizures: Metabolism and Tissue Distribution. <i>Neurology</i>. 1981;31(9):1107-1112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/7196530/pubmed" id="7196530" target="_blank">7196530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pasko.1">
<a name="Pasko.1"></a>Pasko DA, Annich GM. Phenobarbital pharmacokinetics of an infant on ECMO and CVVHD: a case report. Presented to Pediatric CRRT; Orlando FL; 2004.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20388896">
<a name="20388896"></a>Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. <i>JAMA</i>. 2010;303(14):1401-1409. doi:10.1001/jama.2010.410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/20388896/pubmed" id="20388896" target="_blank">20388896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18397299">
<a name="18397299"></a>Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i>. 2008;49(7):1239-1276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/18397299/pubmed" id="18397299" target="_blank">18397299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29957667">
<a name="29957667"></a>Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. <i>Ther Drug Monit</i>. 2018;40(5):526-548. doi:10.1097/FTD.0000000000000546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/29957667/pubmed" id="29957667" target="_blank">29957667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1831121">
<a name="1831121"></a>Pelekanos J, Camfield P, Camfield C, Gordon K. Allergic rash due to antiepileptic drugs: clinical features and management. <i>Epilepsia</i>. 1991;32(4):554-559. doi:10.1111/j.1528-1157.1991.tb04692.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/1831121/pubmed" id="1831121" target="_blank">1831121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7334143">
<a name="7334143"></a>Perry PJ, Stamabaugh RL, Tsuang MT, Smith, RE. Sedative-hypnotic tolerance testing and withdrawal comparing diazepam to barbiturates. <i>J Clin Psychopharmacol</i>. 1981;1(5):289-296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/7334143/pubmed" id="7334143" target="_blank">7334143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rising.1">
<a name="Rising.1"></a>Phenobarbital elixir [prescribing information]. East Brunswick, NJ: Rising Pharma Holdings Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BioRamo.1">
<a name="BioRamo.1"></a>Phenobarbital liquid [prescribing information]. Fort Lauderdale, FL: BioRamo; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cameron.1">
<a name="Cameron.1"></a>Phenobarbital Sodium Injection [prescribing information]. Louisville, KY: Cameron Pharmaceuticals LLC; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Par.1">
<a name="Par.1"></a>Phenobarbital tablets, USP [prescribing information]. Largo, FL: BPI Labs LLC; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24886712">
<a name="24886712"></a>Pugin D, Foreman B, De Marchis GM, et al. Is pentobarbital safe and efficacious in the treatment of super-refractory status epilepticus: a cohort study. <i>Crit Care</i>. 2014;18(3):R103. doi:10.1186/cc13883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/24886712/pubmed" id="24886712" target="_blank">24886712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11071183">
<a name="11071183"></a>Relling MV, Pui CH, Sandlund JT, et al. Adverse Effect of Anticonvulsants on Efficacy of Chemotherapy for Acute Lymphoblastic Leukaemia. <i>Lancet</i>. 2000;356(9226):285-290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/11071183/pubmed" id="11071183" target="_blank">11071183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22999778">
<a name="22999778"></a>Rosenson J, Clements C, Simon B, Vieaux J, Graffman S, et al. Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study. <i>J Emerg Med</i>. 2013;44(3):592-598. doi:10.1016/j.jemermed.2012.07.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/22999778/pubmed" id="22999778" target="_blank">22999778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17589805">
<a name="17589805"></a>Ruggiero A, Buonuomo PS, Maurizi P, Cefalo MG, Corsello M, Riccardi R. Stevens-Johnson syndrome in children receiving phenobarbital therapy and cranial radiotherapy. <i>J Neurooncol</i>. 2007;85(2):213-215. doi:10.1007/s11060-007-9399-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/17589805/pubmed" id="17589805" target="_blank">17589805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sansevere.1">
<a name="Sansevere.1"></a>Sansevere AJ, Bergin AM. Neonatal seizures. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th edition. Lippincott Williams &amp; Wilkins; 2017:chap. 56.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27998379">
<a name="27998379"></a>Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. <i>J Clin Sleep Med</i>. 2017;13(2):307-349. doi:10.5664/jcsm.6470<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/27998379/pubmed" id="27998379" target="_blank">27998379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18853708">
<a name="18853708"></a>Schutte-Rodin S, Broch L, Buysse D, et al, "Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults," <i>J Clin Sleep Med</i>, 2008, 4(5):487-504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/18853708/pubmed" id="18853708" target="_blank">18853708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sezaby.1">
<a name="Sezaby.1"></a>Sezaby (phenobarbital sodium) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3198757">
<a name="3198757"></a>Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. <i>J Clin Invest</i>. 1988;82(6):1826-1832. doi:10.1172/JCI113798<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/3198757/pubmed" id="3198757" target="_blank">3198757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20826962">
<a name="20826962"></a>Singh R, Choudhury M, Kapoor PM, Kiran U. A randomized trial of anesthetic induction agents in patients with coronary artery disease and left ventricular dysfunction. <i>Ann Card Anaesth</i>. 2010;13(3):217-223. doi:10.4103/0971-9784.69057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/20826962/pubmed" id="20826962" target="_blank">20826962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sirven.1">
<a name="Sirven.1"></a>Sirven JI. Approach to the discontinuation of antiseizure medications. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 31, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17586097">
<a name="17586097"></a>St Louis EK, Gidal BE, Henry TR, et al. Conversions between monotherapies in epilepsy: expert consensus. <i>Epilepsy Behav</i>. 2007;11(2):222-234. doi:10.1016/j.yebeh.2007.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/17586097/pubmed" id="17586097" target="_blank">17586097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35219012">
<a name="35219012"></a>Staidle A, Geier C. Phenobarbital and/or benzodiazepines for recurrent alcohol withdrawal: a self-controlled, retrospective cohort study. <i>Am J Emerg Med</i>. 2022;54:263-266. doi:10.1016/j.ajem.2022.02.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/35219012/pubmed" id="35219012" target="_blank">35219012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8348204">
<a name="8348204"></a>Sullivan M, Toshima M, Lynn P, Roy-Byrne P. Phenobarbital versus clonazepam for sedative-hypnotic taper in chronic pain patients. A pilot study. <i>Ann Clinl Psychiatry</i>. 1993;5(2):123-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/8348204/pubmed" id="8348204" target="_blank">8348204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24496695">
<a name="24496695"></a>Sun D, Yu CH, Liu ZS, et al. Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China. <i>J Huazhong Univ Sci Technolog Med Sci</i>. 2014;34(1):146-150. doi:10.1007/s11596-014-1247-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/24496695/pubmed" id="24496695" target="_blank">24496695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tobias.1">
<a name="Tobias.1"></a>Tobias JD. Pentobarbital Sedation for Patients in the Pediatric Intensive Care Unit. <i>J Intensive Care Med</i>. 2000;15:115-120.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10890677">
<a name="10890677"></a>Tobias JD. Tolerance, Withdrawal, and Physical Dependency After Long-Term Sedation and Analgesia of Children in the Pediatric Intensive Care Unit. <i>Crit Care Med.</i> 2000a;28(6):2122-2132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/10890677/pubmed" id="10890677" target="_blank">10890677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17854362">
<a name="17854362"></a>Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. <i>Br J Dermatol</i>. 2007;157(5):934-940. doi:10.1111/j.1365-2133.2007.08167.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/17854362/pubmed" id="17854362" target="_blank">17854362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30075875">
<a name="30075875"></a>Vasquez A, Gaínza-Lein M, Sánchez Fernández I, et al. Hospital emergency treatment of convulsive status epilepticus: comparison of pathways from ten pediatric research centers. <i>Pediatr Neurol</i>. 2018;86:33-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/30075875/pubmed" id="30075875" target="_blank">30075875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29071470">
<a name="29071470"></a>Verrotti A, Moavero R, Panzarino G, Di Paolantonio C, Rizzo R, Curatolo P. The challenge of pharmacotherapy in children and adolescents with epilepsy-ADHD comorbidity. <i>Clin Drug Investig</i>. 2018;38(1):1-8. doi:10.1007/s40261-017-0585-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/29071470/pubmed" id="29071470" target="_blank">29071470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18977996">
<a name="18977996"></a>Wagner CL, Greer FR, American Academy of Pediatrics Section on Breastfeeding, American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. <i>Pediatrics</i>. 2008;122(5):1142-1152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/18977996/pubmed" id="18977996" target="_blank">18977996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20888266">
<a name="20888266"></a>Wang XQ, Lang SY, Shi XB, Tian HJ, Wang RF, Yang F. Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population. <i>Seizure</i>. 2010;19(9):562-566. doi:10.1016/j.seizure.2010.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/20888266/pubmed" id="20888266" target="_blank">20888266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Winter.1">
<a name="Winter.1"></a>Winter ME. <i>Basic Clinical Pharmacokinetics</i>. 5th ed. Wolters Kluwer Health Inc/Lippincott Williams &amp; Wilkins; 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-662511">
<a name="662511"></a>Wolf SM, Forsythe A. Behavior disturbance, phenobarbital, and febrile seizures. <i>Pediatrics</i>. 1978;61(5):728-731.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/662511/pubmed" id="662511" target="_blank">662511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23236549">
<a name="23236549"></a>Zeng Q, Wu Y, Zhan Y, et al. Leukemoid reaction secondary to hypersensitivity syndrome to phenobarbital: a case report. <i>Int J Clin Exp Pathol</i>. 2013;6(1):100-104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/23236549/pubmed" id="23236549" target="_blank">23236549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18475056">
<a name="18475056"></a>Zou CC, Liang L, Fu JF. Type 1 diabetes mellitus in a child with phenobarbital hypersensitivity syndrome. <i>J Endocrinol Invest</i>. 2008;31(4):360-363. doi:10.1007/BF03346371<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenobarbital-drug-information/abstract-text/18475056/pubmed" id="18475056" target="_blank">18475056</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9763 Version 662.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
